

Analysis of non-peptidic compounds as potential malarial inhibitors against *Plasmodial* cysteine proteases via integrated virtual screening workflow

Thommas M. Musyoka^a, Aquillah M. Kanzi^b, Kevin A. Lobb^{a,c} and Özlem Tastan Bishop^{a*}

^aResearch Unit in Bioinformatics (RUBi), Department of Biochemistry and Microbiology, Rhodes University, P.O. Box 94, Grahamstown 6140, South Africa;

^bFaculty of Natural and Agricultural Sciences, Department of Genetics, Forestry and Agricultural Biotechnology Institute (FABI), University of Pretoria, Pretoria, South Africa;

^cDepartment of Chemistry, Rhodes University, P.O. Box 94, Grahamstown 6140, South Africa

* Corresponding author. Email: O.TastanBishop@ru.ac.za

Abstract

Falcpain-2 (FP-2) and falcpain-3 (FP-3), haemoglobin-degrading enzymes in *Plasmodium falciparum*, are validated drug targets for the development of effective inhibitors against malaria. However, no commercial drug-targeting falcpains has been developed despite their central role in the life cycle of the parasites. In this work, *in silico* approaches are used to identify key structural elements that control the binding and selectivity of a diverse set of non-peptidic compounds onto FP-2, FP-3 and homologues from other *Plasmodium* species as well as human cathepsins. Hotspot residues and the underlying non-covalent interactions, important for the binding of ligands, are identified by interaction fingerprint analysis between the proteases and 2-cyanopyridine derivatives (best hits). It is observed that the size and chemical type of substituent groups within 2-cyanopyridine derivatives determine the strength of protein–ligand interactions. This research presents novel results that can further be exploited in the structure-based molecular-guided design of more potent antimalarial drugs.

Keywords: malaria, homology modelling, docking, molecular dynamics, falcpains

1. Introduction

Malaria is an infectious disease caused by a diverse group of erythrocytic protozoan parasites of the genus *Plasmodium*. It remains an exigent public health problem in the tropical areas of Africa, South America and parts of Asia and continues to take its toll in morbidity and mortality with half of the world's population under a permanent risk of infection leading to more than half a million deaths annually (WHO, 2013). Five *Plasmodium* species, namely *P. falciparum* (*Pf*), *P. vivax* (*Pv*), *P. ovale* (*Po*), *P. malariae* (*Pm*) and *P. knowlesi* (*Pk*), are known to infect humans with *Pf* responsible for more than 90% of the

malarial fatalities reported in sub-Saharan Africa. The predominance of *Pf* is attributed to its adaptability (Ashley, McGready, Proux, & Nosten, 2006; Prugnolle et al., 2011). Although the high occurrence of the Duffy negative trait among African populations lowers the threat posed by *Pv*, it is the most frequent and widely causative agent of benign tertian malaria in other parts of the world (Mendis, Sina, Marchesini, & Carter, 2001). In addition to the listed human malarial parasite forms, several other *Plasmodium* species, which infect non-human laboratory models, have been identified and are of significant importance in understanding the parasite biology, the host–parasite interactions and in the drug development process (Langhorne et al., 2011).

Malaria still remains a major threat primarily due to the emergence of drug-resistant parasitic mutations, particularly to available frontline antimalarial drugs, a situation aggravated by the absence of an effective vaccine that has remained elusive to date (Hartjes, 2011). In addition, the recent reports indicating the emergence of resistance to artemisinin, which is the cornerstone to the current artemisinin-based combination therapies (ACT), emphasizes the continued need for identification of new drugs with novel scaffolds and mode of action (Mok et al., 2011; Saralamba et al., 2011). A formidable hurdle against successful elimination of malaria is the identification of a broad range of drugs targeting common druggable targets in both the active human forms of *Plasmodium* and the circulating wild species. Several *Plasmodium* drug targets including but not limited to falcipains (FPs) (Marco & Miguel Coteron, 2012), serine/threonine protein phosphatase 5, serine repeat antigens, apicoplast-targeted tRNA-guanine transglycosylase (Gupta et al., 2015), *Pf* lactate dehydrogenase (Thillainayagam et al., 2014) and heat shock proteins (Hatherley, Blatch, & Tasthan Bishop, 2014) have been identified. In the current study, our focus is on the falcipains that are validated drug targets (Teixeira, Gomes, & Gomes, 2011).

The FPs are a homologous family of four *Pf* cysteine proteases *viz.* FP-1, FP-2, FP-2' and FP-3, which are fairly similar to papain-like human cathepsins but with eccentric features such as longer prodomains and a 14 amino acid (aa) insert between highly conserved residues near the C-terminus (Rosenthal, 2011). FP-1 is distantly related to the other FPs, and its role in the *Plasmodium* development process remains unclear (Kumar et al., 2007). FP-2 and FP-2' have a ~99% sequence identity and differ only in three amino acids; none of which is located in the active-site cavity (Mane et al., 2013). Through chemical inhibitory studies against FP-2 and FP-3 as well as FP-2 gene disruption experiments, both enzymes have been shown to play indispensable roles either solely or in concert with other proteases, as they possess a nucleophilic thiolate group in their active site's cysteine residue which is key for amide bond cleavage (Ehmke et al., 2011). These two proteases of the clan CA family are not only key in the haemoglobin degradation pathway which is the sole source of amino acids for the exponential growth and proliferation of the parasites but also in the erythrocyte egression and rupture process (Marco & Miguel Coteron, 2012; Rosenthal, 2011).

Several attempts combining chemical synthesis and *in silico* screening approaches have been undertaken in the past decade to discover and optimize inhibitors targeting parasite proteases of infectious agents, leading to two broad classes of chemical compounds *viz.* peptidomimetic and non-peptidic small molecules. Such attempts have successfully led to the discovery of several therapies in other diseases such as those against hepatitis C virus (HCV) (Melnikova, 2008) and human immunodeficiency virus (HIV) (Flexner, Bate, &


Kirkpatrick, 2005). As reviewed by Mane et al., scientific efforts to develop FP-2 and FP-3 inhibitors have mainly realised peptide based compounds (Mane et al., 2013) such as α -ketoamides (Lee et al., 2003), peptidyl aldehydes (Rosenthal, Lee, & Smith, 1993), E-64 epoxysuccinyl derivatives (Schulz et al., 2007); but none has ever been commercialized as an antimalarial drug due to inherent poor pharmacological profiles as well as susceptibility to degradation by host enzymes (Ettari et al., 2010). The identification and validation of small non-peptide FP inhibitors is expected to overcome these shortcomings, and so far several compounds belonging to isoquinolones, chalcones and others (Batra, Sabnis, Rosenthal, & Avery, 2003; Domínguez et al., 2005; Li et al., 1995; Liu, Wilairat, & Go, 2001) have been shown to possess antimalarial potency either on whole *Pf* parasite cultures or directly on FP-2 protein at low micromolar ranges. Coterón et al., recently reported a new class of compounds that belong to the heteroaryl nitrile class hitherto vouched as the most potent. Through a sequential lead optimization process, several 5-substituted-2-cyanopyrimidines derivatives (CPs) with FP-2 and FP-3 inhibitory potency and anti-*plasmodial* activity in the picomolar to low nanomolar ranges were obtained (Coterón et al., 2010).

To facilitate the discovery of novel potential antimalarial compounds, our aim was to set up a reliable integrated virtual screening workflow comprising of homology modelling, molecular docking, molecular dynamics (MD) and binding free energy (BFE) calculations, which can be used to identify potential non-peptide compounds against *plasmodial* cysteine proteases. A diverse set of compounds from the literature with reported potency against FP-2 and/or FP-3 were used to determine their mode of interaction with FP-2 and FP-3 and their *plasmodial* homologues (targets) and their selectivity towards the human papain-like cathepsins (off-targets). These compounds are CPs (Coterón et al., 2010), chalcones (Domínguez et al., 2005; Li et al., 1995; Liu et al., 2001), isoquinolones (Batra et al., 2003) and thiosemicarbazones (Chipeleme, Gut, Rosenthal, & Chibale, 2007; Chiyanzu et al., 2003; Greenbaum et al., 2004). After docking, guided by molecular-docking energy scores, compounds that showed the best scores were further put through MD simulations and interaction energy quantified via BFE calculations. The dynamical behaviour and strength of interactions of the protein–compound complexes were analysed to describe the possible binding modes, the interacting structural elements as well as the stability of the complexes, information which may be potentially useful in the drug discovery and development process of novel broad-spectrum antimalarial agents. The key amino acid residues contributing to different interactions with potential inhibitors were identified. Overall, the following observations were made: (i) there exist amino acid composition differences in the subsites of *plasmodial* FP-2 and FP-3 homologues and human cathepsins, which could be important for inhibitor design; (ii) out of the four classes of compounds used, the CPs are the best docked inhibitors with very low BFEs against *plasmodial* proteases compared to human cathepsins, thus showing a degree of selectivity; (iii) The substituent chemical groups in the main CPs scaffold determine the overall potency of the individual derivatives.

2. Methods and materials

The flow diagram of the methodology followed in this study is presented in Figure 1 and the details are given below.

Figure 1. Graphical workflow for identification of FP-2/3 homologues (sequence and structure) and analysis of non-peptidic compounds as potential inhibitors via *in silico* approaches. Bold and in brackets are the key databases, web servers and tools used.



2.1. Sequence retrieval

FP-2 and FP-3 protein sequences (accession numbers: PF3D7_1115700 and PF3D7_1115400, respectively) were retrieved from PlasmoDB version 9.3 (Aurrecochea et al., 2009) and used as queries to retrieve homologue sequences of other *Plasmodium* species and humans using the BLASTP tool in the PlasmoDB and the NCBI database (Sayers et al., 2009), respectively. To confirm whether the retrieved hits were the true orthologues, reverse BLAST searches were performed. Only sequences with significant query coverage, *E*-values lower than 1.0×10^{-5} were selected (Text S1). Crystal structures of the human cathepsins (Cat K [PDB ID: 3OVZ], Cat L [PDB ID: 3OF8], Cat S [PDB ID: 1NPZ] together with those of FP-2 [PDB ID: 2OUL] and FP-3 [PDB ID: 3BWK] were retrieved from the Brookhaven Protein Data Bank (PDB) (Bernstein et al., 1977).

2.2. Multiple sequence alignment

Multiple sequence alignment (MSA) was done using web-based servers, namely MAFFT (Kato, Misawa, Kuma, & Miyata, 2002) and PROMALS3D (Pei, Kim, & Grishin, 2008) and

alignment outputs compared to determine the alignment accuracy. For MAFFT program, the following sequence alignment parameters were utilized; substitution matrix was set as BLOSUM62 scoring matrix (Eddy, 2004), gap opening and extension penalty of 1.53 and .123, respectively. The number of tree-building steps was adjusted to 2 with maximum iteration set at 2. For PROMALS3D, structural information from the crystal structures of FP-2 and FP-3 was added to guide the alignment using default parameters with an exception of PSI-BLAST expect value which was adjusted to .0001. Alignment parameter for sequences within groups in the first alignment stage was set to the slow but more accurate PROMALS algorithm (Jimin Pei & Grishin, 2007). The initial alignment was done for the full-length protein sequences and trimmed using JalView software (Waterhouse, Procter, Martin, Clamp, & Barton, 2009) to obtain the catalytic domain portions of the cysteine proteases that were realigned. From the MSA, sequence identities, similarities and conserved regions were identified. Subsite residues were extracted from the alignment into a Fasta file and submitted to WebLogo (Crooks, Hon, Chandonia, & Brenner, 2004), a web-based sequence logo generator, to determine the residue conservation at these specific positions in a WebLogo presentation.


2.3. Homology modelling

For each of the FP-2 and FP-3 *plasmodial* homologues, the HHpred web server (Soding, Biegert, & Lupas, 2005) was utilized to search for suitable templates for building high-quality models to be used in the subsequent docking and molecular dynamics steps. Selection of predicted templates was based on the one with the highest sequence identity, coverage and resolution. Two templates were retrieved from PDB, namely [PDB ID: 2OUL] (Wang et al., 2007) and [PDB ID: 3BWK] (Kerr, Lee, Farady et al., 2009) for FP-2 and FP-3, respectively. Template quality validation was performed using MetaMQAPII (Benkert, Biasini, & Schwede, 2011), ANOLEA (Melo, Devos, Depiereux, & Feytmans, 1997), QMEAN (Benkert, Tosatto, & Schomburg, 2008) and PROCHECK (Laskowski, MacArthur, Moss, & Thornton, 1993). Manual adjustments were made in the template-target alignment files where applicable by comparing the HHpred and PROMALS3D structural alignment output with that of MAFFT. For each homologue, 200 models were calculated using MODELLER version 9.10. Models were ranked using DOPE Z scores (Shen & Sali, 2006). The top three models with the lowest energy scores for each protein were further validated by MetaMQAPII and PROCHECK. Disulphide bond formations in the models were assessed through Protein Interaction Calculator (PIC) web server (Tina, Bhadra, & Srinivasan, 2007) in relation to the FP-2 and FP-3 templates. The top best model for each protein was selected for the subsequent steps of molecular docking and molecular dynamics.

2.4. Compounds

All the compounds (CPs, chalcones, isoquinolones, thiosemicarbazones) and associated activity data used in this study were retrieved from published data. In DS (Discovery Studio version 3.1, Accelrys Software Inc. Discovery Studio Modelling Environment, San Diego: 2011), compound 2D structures were sketched and converted to a 3D format. The 3D geometry of structures was cleaned and optimized to attain stable conformations with minimum energy. Figure 2 shows the chemical 2D structures of all compounds drawn using MarvinSketch 6.1.0 (Marvin Calculator Plugin and Chemical Terms Demo ChemAxon).

Figure 2. 2-D structures of the different sets of non-peptidic compounds used in this study.



2.5. Protein–ligand docking

In order to explore the likely binding modes of the CPs, chalcones, isoquinolenes, thiosemicarbazones onto the substrate pocket of FP-2 and FP-3, the modelled 3D homologues and crystal structures of human cathepsins, molecular docking was performed using AutoDock4.2 (Morris et al., 2009). Prior to docking, identical chain sequence information and cocrystallized water molecules in protein crystal structures were deleted using DS. AutoDock tools (ADT) were used to prepare the ligands, protein structures and calculated models for the actual modelling simulations. Using the Gasteiger–Hückel method in ADT, the partial atomic charges of the ligands were assigned. Cubic grid points were set at 70, 70 and 65 along the x, y and z directions, respectively, for all the ligands with a grid spacing of .3472 Å. A centroid point was generated on the catalytic Cys42 of FP-2 and corresponding positions in all homologues. The grid box spanned an area of residues around a 12 Å radius. Docking simulations were carried out locally on a Linux-based cluster with the parameters set as follows: genetic algorithm (GA) and the Lamarckian genetic algorithm variant were used for receptor–ligand conformational search. The population size was set at 150, 100 GA runs, maximum energy evaluations of 450,000 and maximum number of generations set at 27,000. Cluster analysis for docked results was done using a root mean square (RMS) tolerance of 2.0 Å. Ligands in the best predicted poses were visually analysed to identify interactions of specific interest using DS. An energy heat map was created using the gnuplot program (Gnuplot (4.6.6) [Computer software], <http://gnuplot.sourceforge.net/>). An ad hoc Perl script utilizing LigPlot+ subroutines (Laskowski & Swindells, 2011) was used to determine the hydrogen bonding and hydrophobic interactions between each ligand and active-site residues. From the docking results, protein–compound complexes with low-docking energy scores were selected for the molecular dynamics and BFE calculations.

2.6. Molecular dynamics simulations

To determine the stability and map the intermolecular interactions of CPs with the cysteine proteases, molecular dynamics (MD) simulations of up to 10 nanoseconds (ns) were performed using GROMACS 4.5.5 package (Pronk et al., 2013) with AMBER96 force field (Kollman, 1996). The protonation state of all the protein's ionisable amino acid groups at a pH of 5.0 were assigned using the DS protein utility module, and protonation was performed accordingly with the pdb2gmx functionality of GROMACS to mimic the acidic environment of the lysosomal vacuole where the proteins reside (Hogg et al., 2006). Ligand topology files were generated using ACPYPE interface (Sousa da Silva & Vranken, 2012) and Open Babel (O'Boyle et al., 2011). The protein-CP complexes were solvated in a triclinic box of dimension 17.5 Å and the flexible SPC water model was used to create an explicit continuous water model. The system was neutralized to a total charge of zero by randomly replacing water molecules with .15 M counter ions (Na^+ and Cl^-). To avoid high-energy interactions and steric clashes, the system was subjected to a steepest descent energy minimization process without constraints until a tolerance of $1000 \text{ kJ mol}^{-1} \text{ nm}^{-1}$ was obtained. Each energy minimized system was then equilibrated in the canonical ensemble (for 200 ps through the NVT ensemble set at 300 K) and subsequently in the isothermal-isobaric ensemble (for 200 ps). The NPT conditions were set at 1.0 bar of pressure in all directions and a pressure coupling constant (τ_P) of 2.0 ps using the V-rescale thermostat (Bussi, Donadio, & Parrinello, 2007) and the Parrinello-Rahman barostat (Parrinello, 1981) algorithms, respectively. The values of the isothermal compressibility were set at $4.5 \times 10^{-5} \text{ bar}^{-1}$ for water simulations. The pre-equilibrated systems were thereafter subjected to a 10 ns production run with an integration time step of 2 femtoseconds (fs) while maintaining temperature and pressure. All bond lengths during equilibration and production runs were constrained utilizing the LINCS algorithm (Hess, Bekker, Berendsen, & Fraaije, 1997). Long-range electrostatic interactions were approximated by the particle-mesh Ewald algorithm (Petersen, 1995) with a .16 nm Fourier grid spacing and a fourth-order interpolation, while the cut-off distances for the calculation of Coulomb and van der Waal interactions were set at 1.4 nm. During the sampling process, trajectory snapshots were stored at every 2 ps for structural analysis.

MD trajectories were analysed using the GROMACS in house tools in conjunction with LigPlot+. In house ad hoc Perl and Python scripts were used to automate the analysis process. Xmgrace of Grace 5.1.21 was used to plot MD graphical displays, while protein-ligand complex visualizations were performed using PyMOL software (The PyMOL Molecular Graphics System, Version 1.6.0.0 Schrödinger, LLC.)

2.7. BFE calculations

According to the molecular mechanics/Poisson-Boltzmann surface area (MM-PBSA), the strength of interactions between the different protease-CP complexes (total BFE) was determined using g_mmpbsa tool (Kumari, Kumar, & Lynn, 2014). Using the single trajectory approach, the calculations were performed on 4000 snapshot structures extracted at 2 ps intervals over the last 8 ns of each of the system's GROMACS generated trajectories. The following set of equations was used to calculate the BFE:

$$\Delta G_{bind} = G_{complex} - (G_{receptor} + G_{ligand}) \quad (1)$$

$$\Delta G_{bind} = E_{gas} + G_{sol} - T\Delta S \quad (2)$$

$$E_{gas} = E_{int} + E_{vdw} + E_{ele} \quad (3)$$

$$G_{solv} = G_{pol} + G_{SA} \quad (4)$$

$$G_{SA} = \gamma_{SASA} + b \quad (5)$$

where $G_{complex}$, $G_{receptor}$ and G_{ligand} denote the absolute free energy of the protein–ligand complex, apoprotein and ligand, respectively. E_{gas} , E_{int} , E_{vdw} and E_{ele} signify gas-phase, internal, van der Waals and electrostatic energies in that order. The solvation-free energy (G_{solv}) is composed of polar (G_{pol}) and non-polar (G_{SA}) terms: the former is estimated from a solution of the linear Poisson–Boltzmann (PB) equation, and the latter from the solvent accessible surface area (SASA) using a water probe of radius 1.4 Å, an offset value (b) of 3.84928 kJ mol⁻¹ and surface tension proportionality (γ) set at .0226778 kJ mol⁻¹ Å⁻². T and S correspond to temperature and solute entropy, respectively. To decipher key determinants involved in the ligand-binding process, the BFE energetic contributions by van der Waals forces, electrostatic energy, as well as polar and non-polar solvation energy were decomposed for each the protein–ligand complex systems. A per-residue decomposition analysis of the contribution of each protein residues to the three components of BFE was also calculated.

2.8. System specifications

Unless otherwise stated, all the computational analysis including 3D model building and MSA were performed on a Linux Intel Xeon workstation equipped with four 3.10 GHz parallel E3-1220V2 processors, Quadro K600/PCIe/SSE2 graphics card and 31.1 GB RAM. Molecular dynamics and binding BFE calculations were performed using a local cluster, and the Tsessebe cluster (Sun) high-performance computing unit at the CHPC (Centre for High Performance Computing, n.d.), Cape Town, South Africa. All web servers and databases used for data-set retrieval and analysis are listed in Supplementary Table S1.

3. Results and discussion

3.1. Sequence analysis

Besides the protein sequences of FP-2 and FP-3, seven *plasmodial* and three human homologues were retrieved from PlasmoDB and NCBI databases (Table 1). That is, the retrieved protein sequences were all FP-2 and FP-3 orthologues was strongly supported by the reverse BLAST results. Interestingly, in most of the reverse BLAST results, the first hit was to FP-3 rather than FP-2, even though the initial BLAST search was performed with FP-2 as query sequence, indicating that some of the homologue proteins are not accurately annotated in the literature.

Table 1. A summary of FP-2 and FP-3 homologues from different *Plasmodium* species and *Homo sapiens*.


Accession number	Common name (abbreviation)	Source organism (abbreviation)	% SI		Position in whole sequence	Catalytic domain numbering
			FP-2	FP-3		
PF3D7_1115700	Falcipain-2 (FP-2) [§]	<i>P. falciparum</i> (Pf)	100	66	244–484	1–243
PF3D7_1115400	Falcipain-3 (FP-3) [§]		66	100	250–492	1–249
PVX_091415	Vivapain-2 (VP-2)	<i>P. vivax</i> (Pv)	62	66	246–487	1–242
PVX_091410	Vivapain-3 (VP-3)		57	57	253–493	1–241
PCHAS_091190	Chaubapain-2* (CP-2)	<i>P. chabaudi</i> (Pc)	50	48	231–471	1–241
PKH_091250	Knowlesipain-2* (KP-2)	<i>P. knowlesi</i> (Pk)	57	57	252–495	1–244
PVX-091260	Knowlesipain-3* (KP-3)		57	60	240–479	1–240
PBANKA_093240	Berghepain-2* (BP-2)	<i>P. berghei</i> (Pb)	51	47	228–468	1–241
PY00783	Yoelipain-2* (YP-2)	<i>P. yoelii</i> (Py)	48	47	232–472	1–241
gi 157830076	Cathepsin-K (Cat K)	<i>H. sapiens</i> (Hs)	38	41	115–329	1–215
gi 313754424	Cathepsin-L (Cat L)		37	38	113–333	1–221
gi 30749675	Cathepsin-S (Cat S)		36	37	115–331	1–217

Notes: Marked with § indicates the query sequences while * indicates sequences renamed for convenience. % SI (Percentage Sequence Identity) is based on the catalytic domain of FP-2 and FP-3.

MAFFT MSA output after additional minor manual adjustments was considered to be the best for the catalytic domain. Sequence identities (SI) were calculated (Table 1) and conservation of protein sequence features were determined (Figure 3(a)). From the primary sequence alignment, 45 aa positions (highlighted in green) inclusive of the clan C1A characteristic catalytic triad residues, namely Cys, His and Asn (marked with an asterisk) and the Gly-Cys-X-Gly-Gly motif, were fully conserved in all protein sequences. In addition, up to 18 aa positions were only conserved in the *plasmodial* proteases (highlighted in blue), whereas 23 aa positions were unique in the human cathepsins (highlighted in black). Up to 34 aa positions were conserved exclusively in the rodent *plasmodial* proteases (highlighted in grey). Four aa positions were conserved only in the human *plasmodial* proteases (highlighted in red). Two clearly visible amino acid inserts present only in the *plasmodial* proteases were observed, one at the N-terminal and the other near the C-terminal (boxed). The first insert of about 17 residues (commonly referred to as nose) has been shown to be important for the correct folding of the catalytic domains of FP-2 and FP-3 before assuming its final active conformation (Pandey & Dixit, 2012). The second insert consisting of approximately 14 aa (commonly referred as arm) structurally forms a highly flexible β -hairpin. Wang et al., associated it with the haemoglobin (substrate) binding process (Wang et al., 2007). Both in FP-2 and FP-3, the arm is fairly conserved, while in the rest of the *plasmodial* orthologues, variations were observed. Although it is yet to be determined, it can be assumed that the inserts play similar functions in the other *plasmodial* homologues as established in FP-2 and FP-3. Interestingly, the rodent *plasmodial* proteases had a unique aa pattern at the arm region compared to the human *plasmodial* forms. Besides the catalytic cysteine residue, all *plasmodial* proteases had a total of eight cysteine residues in the catalytic domain which form a set of four disulphide bonds. In contrast, the human

cathepsins had only six extra cysteine residues capable of forming three sets of disulphide bonds.

Figure 3. Sequence analysis and subsite amino acid composition of FP-2, FP-3 and homologues. (a) MAFFT multiple sequences output of FP-2/3 and homologues showing conservation of functional and structural residues. The Clan CA characteristic catalytic triad residues are indicated with an asterisk. The two unique inserts in all *plasmodial* proteases are indicated with a black dashed box. (b) Summary of the amino acid composition (table) and conservation (sequence logo) of all four subsites for FP-2/3 and homologues as determined by WebLogo. The relative height of each letter and total height indicates the relative frequency of corresponding aa and information content respectfully per site in all the sequences.



A characteristic feature of cysteine proteases is the presence of an active-site pocket constituted by residues surrounding the catalytic triad. It is situated in a cleft between the structurally conserved R and L domains and consists of subsite S1, S2, S3 and S1' (Kerr, Lee, Pandey et al., 2009). By comparing the active-site pockets of human cathepsins and *plasmodial* cysteine proteases, the structural information that controls the selectivity and functioning of these proteins can be determined, a key feature in designing efficacious and more potent drugs. As shown in Figure (3(b)), it was observed that S1 and S3 subsite residues are fairly conserved, while S2 as well as a significant number of aa positions in S1' are highly varied. Although at the sequence level the effect of these observations on the structure and functions of the proteins cannot be determined, it is well known that S2 plays a key role in the specificity of ligand binding (Pandey & Dixit, 2012). Amino acid residues

Gln36 (S1), Asn173 (S2) and Asn204 (S1'), which are key in polarizing His174 (S1') during catalysis, are conserved in all proteases with an exception of the S2 position of Cat L which has Asp residue (numbering as per FP-2 catalytic domain). In S1, the two conserved cysteine residues (Cys39 and Cys80) form one of the four disulphide bridges critical in stabilizing the proteins (Hogg et al., 2006). The small polar Gly40 residue is conserved in all homologues except in the rodent associated proteases where it is replaced with a biochemically related non-polar alanine residue. Even though the fifth position of S1 was highly varied among the proteases, residues occupying this position were all polar suggesting a conserved function. S2, which has been defined as the major pocket that determines ligand specificity in cysteine proteases, was mainly occupied by hydrophobic residues as per previous observation (Pandey & Dixit, 2012). A striking difference between the human *plasmodial* homologues and the rest including the cathepsins is the presence of a polar charged residue at the S2 pocket's hollow end of human *plasmodial* proteases, while the rest have a small uncharged residue at the same position. Zhao et al., observed that the S2 of human Cat K was constituted by hydrophobic residues, but from our results, this was the case only with Cat L and Cat S (Zhao et al., 1997). S2 pocket volume of FP-2 vis-à-vis FP-3 and VP-2 vis-à-vis VP-3 have been shown to vary in size indicating that careful consideration of the size and shape of inhibitor groups targeting this site have to be carefully determined. FP-2 has less bulky Leu84 and Leu172 at the S2 opening groove while in FP-3, these residues are replaced with more bulky Tyr86 and Pro174 resulting in a narrower distal end (Sabnis, Desai, Rosenthal, & Avery, 2003). In VP-3, the area between S1' and S2 subsites is folded inwards making the S2 narrower than in VP-2 (Desai & Avery, 2004). In the rodent *plasmodial* proteases, the S2 opening residues are highly conserved with less bulky Ile85 and Ala173 on either side. It was observed that S3 has a rich highly conserved glycine component, a feature that provides additional protease-substrate stability via hydrogen bonding (Desai & Avery, 2004). At the opening of the V-shaped cleft, there exists a highly conserved tryptophan residue in all the proteases, which has been found to form hydrophobic interaction with substrates (Sabnis et al., 2003).

3.2. Homology modelling and quality validation

Seven high-quality protein models of the catalytic (mature) domains of *Plasmodium* FP-2 and FP-3 homologues, VP-2 (Vivapain-2), VP-3 (Vivapain-3), BP-2 (Berghepain-2), CP-2 (Chaubapain-2), KP-2 (Knowlesipain-2), KP-3 (Knowlesipain-3) and YP-2 (Yoelipain-2) were calculated using MODELLER version 9.10. The position of the catalytic domain for each of the FP homologues in the whole sequence and the adopted catalytic domain numbering is shown in Table 1. For each of these proteins modelled, two templates (PDB IDs: 2OUL and 3BWK) were consistently identified from HHpred web server (Supplementary Table S2). To attain alignment accuracy, the secondary structure prediction in the HHpred alignments were considered, and HHpred, PROMALS3D and MAFFT alignments were compared; if necessary hand adjustments were done (Figure 3(a)). The suitability of the obtained templates was scrutinized by assessing the target sequence coverage and resolution. Furthermore, template quality assessment results by MetaMQAPII, ANOLEA and Ramachandran plot showed that the two selected templates were suitable. Depending on the sequence identity score, KP-2 was modelled using 3BWK, while BP-2, CP-2, YP-2 used 2OUL and the rest used both templates. All resulting 3D models were assessed by discrete optimized potential energy (DOPE)-Z score, global distant test-total score (GDT-TS) score as

well as by the same programs used for template quality check. From Supplementary Table S2, KP-3 had the best normalized DOPE-Z and GDT-TS scores. Shen and Sali estimated that DOPE Z-score below -0.5 are indicators of a protein structure near to the native form, as such it is evident that all models generated were of high quality (Shen & Sali, 2006). The colour code presentation of MetaMQAPII results indicated that they had been accurately modelled, except for some loop regions in some cases (blue for accurate regions and red for problematic regions) as shown in Supplementary Figure S1. Overall, the obtained evaluation results indicated that the models are of high quality, especially in the active site region, and can be used for inhibitor-docking experiments.

3.3. Docking studies

A total of 20 non-peptide inhibitors of the chemical classes of isoquinolines, chalcones, thiosemicarbazones and CPs were docked to 12 cysteine proteases. Out of these 12, three were human cysteine proteases, namely Cat L, Cat S and Cat K. They were used to assess protein–ligand interaction characteristics that could provide significant information with regard to selectivity. Two were crystal structures of FP-2 and FP-3 (2OUL and 3BWK, respectively) and the remaining seven proteins were the 3D models of FP-2 and FP-3 *Plasmodium* homologues. The results are presented in Figure 4 and Table 2. The CP series of compounds exhibited the lowest docking free energy of binding (strong affinity) and lowest inhibition constants against almost all proteins compared to the other classes of compounds used, and thus were selected for the subsequent steps of MD simulations and BFE calculations.

Figure 4. A heatmap showing the interaction free energies of all compounds when docked against *plasmodial* cysteine proteases and human cathepsins using AutoDock4.2. The energy code ranges from high (yellow) to low (black).




Table 2. AutoDock inhibition constants (μM) of the CPs onto FP-2 and FP-3 and homologues. Enclosed in brackets are the IC_{50} from wet laboratory assays. The references for the assays were given in the main text.

CMPD	Protein											
	<i>Plasmodial</i>									Human homologues		
	FP-2	FP-3	VP-2	VP-3	KP-2	KP-3	BP-2	CP-2	YP-2	Cat S	Cat L	Cat K
CPA	.80 (.0005)	.33 (.006)	.14	3.32	2.51	.45	.38	.54	1.02	1.68	2.09	.24
CPB	.78 (<.0005)	.11 (.011)	.52	3.14	2.71	.18	.39	.85	3.42	3.19	2.27	.43
CPC	.53 (.0005)	.12 (.006)	.12	1.61	1.22	.21	.34	.36	.50	.71	.79	.13
CPD	1.23	.35	.46	2.63	1.06	.36	.58	.32	.13	6.80	.32	1.08
CPE	1.62	.27	.72	1.91	1.35	.48	.38	.47	.82	11.16	.36	1.14
CPF	1.58	.29	.36	2.34	1.91	.20	.94	.81	1.68	12.19	.31	.94
CPG	.16	.03	.02	.81	.11	.04	.05	.16	.04	.27	.14	.10
CPH	.08	.01	.01	.25	.06	.02	.01	.04	.04	.16	.06	.13
CPI	.08	.01	.01	.06	.02	.02	.03	.03	.02	.22	.03	.15
CL-A	1.63	3.50	9.03	2.98	2.25	1.60	4.10	2.82	6.10	14.95	5.02	2.36
CL-B	15.64	22.94	4.18	28.42	8.58	18.86	12.27	6.60	10.26	7.20	21.99	12.36
CL-C	3.57 (1.80)	2.08	1.53	8.62	4.60	7.85	2.45	2.94	1.52	7.18	6.31	.92
IQ-A	.34 (3.00)	.58	.34	.63	.85	.60	.17	.08	.37	.33	.54	.24
IQ-B	3.41 (3.00)	5.41	3.55	5.75	4.02	5.84	2.50	3.73	4.45	4.66	5.88	1.67
TSC-A	24.99	40.27	15.17	42.72	26.92	18.64	14.00	12.67	14.11	33.75	26.48	22.12
TSC-B	5.25 (4.40)	10.79	11.14	10.51	14.58	6.45	23.34	19.48	15.47	12.58	9.35	19.20
TSC-C	20.28 (10.00)	35.73	14.57	87.47	33.82	35.30	22.57	27.24	31.24	36.38	14.69	30.51
TSC-D	12.72 (5.80)	45.65	13.09	48.25	30.33	14.39	13.83	42.55	24.61	42.84	5.88	62.04
TSC-E	9.84 (3.80)	40.69	15.66	43.92	10.84	8.54	19.89	12.99	16.43	52.21	13.66	37.77
TSC-F	2.13 (2.25)	2.13	1.87	1.85	2.29	3.75	.21	.29	.87	3.97	1.72	3.60


Note: CMPD = Compound, CPX = 2-cyanopyrimidine, CL = Chalcone, IQ = Isoquinolene, TSC = Thiosemicarbazone.

In Table 2, thiosemicarbazones had high free energy of binding which implied lower estimated binding affinities, and consequently, higher inhibition constants. AutoDock inhibition constants of these compounds onto FP-2 were comparable with results obtained from experimental enzyme assays (Chiyanzu et al., 2003; Greenbaum et al., 2004; Liu et al., 2001). In both approaches, inhibition constants were at μM levels, although in some cases the experimental values were half or even a third of the docking values. Docking results were varied between 2.13 and 24.99 μM . Chalcones showed the same trend as thiosemicarbazones both in *in silico* results and experimental data (Li et al., 1995). The two docked isoquinoline derivatives showed varied binding affinity. Isoquinoline-A had considerably good docking free energies against all proteins compared to thiosemicarbazones and chalcones. Interestingly, while assay results were indicating inhibition at 3 μM against FP-2 for both compounds (Batra et al., 2003) the *in silico* result for isoquinoline-B agreed, but the isoquinoline-A was 10-fold less. In fact, isoquinoline-A was good in the context of *Plasmodium* homologues, with estimated inhibition constants in the nanomolar range. Even though its uniform docking free energy among *Plasmodium* proteins and the human cathepsins raises concerns of selectivity, it could be used as a starting

scaffold for further studies involving chemical modifications leading to derivatives with increased potency and safety profiles.

Among the CPs, compound CPG, CPH and CPI had the lowest inhibition constants as determined by AutoDock (See Table 2) and had interaction energies ranging between, -8 and -10 kcal mol⁻¹ across all homologues (Figure 4). According to docking results, these inhibitors had high binding affinity for FP-3 than FP-2. The estimated inhibition constants were all in the nanomolar range. Interestingly, experimental inhibition constants for CPA-CPC for FP-2 and FP-3 were much lower than the *in silico* results (Coterón et al., 2010). Compounds with a cyclohexyl or cyclopentyl at the P2 position (corresponds to S2 in protease) and pyridinyl–phenyl combinations yielded antiparasitic activity at subnanomolar and nanomolar levels against FP-2 and FP-3, respectively (Coterón et al., 2010). According to Table 2, CPs are better inhibitors against FP-3, VP-2 and KP-3 as compared to FP-2, VP-3 and KP-2, respectively. In the case of vivapains, Desai et al., (Desai & Avery, 2004) observed that VP-2 was more sensitive to inhibitors than VP-3 as its S2 opening was wider. In contrast, the other classes of inhibitors seemed to inhibit FP-2 more than FP-3. The activity of CPs seemed to be largely influenced by the chemical composition of R1 and R2 (Figure 2). Compound CPG, CPH and CPI were the strongest binders against all proteases (see Figure 4 and Table 2). Interestingly, R1 group that was the same in CPA-CPC, CPD-CPF and CPG-CPI seemed to affect the overall docking energy score in the human cathepsins and falcipains. CPs had a cyclopentyl or cyclohexyl at R2 which bound at or near the S2 position. Compounds CPC, CPF and CPI which had a cyclohexyl group at R2 exhibited lower docking energies and inhibition constants when in complex with most proteins. This was dependent on whether the opening of S2 was wide enough to allow the entry of the R2 group. Rosenthal et al., (Rosenthal, Wollish, Palmer, & Rasnick, 1991) previously established that the S2 of FP-2 preferred the phenyl group of phenylalanine, a group that is chemically similar to the cyclohexyl. Additionally, the binding poses of CPs varied in different proteins as seen in Figure 5, for example for CPG, CPH and CPI, thus explaining the differential docking energies and inhibition constants in Figure 4 and Table 2. In Cat K (Figure 5(a)), CPG fits in well interacting with most subsite residues as compared to CPH and CPI, hence the resulting low docking energy and inhibition constant. In Cat L, the three compounds have similar pose resulting in almost similar inhibition constants (Figure 5(b)). For FP-2 and FP-3, the gate to S2 seems to play a key role in determining what goes in. In FP-2, the compounds can access and thus interact with S2 subsite residues (Figure 5(c)), while in FP-3, the narrower gate hinders their entry (Figure 5(d)). Despite this observation, FP-3 has lower docking energies and inhibition constants. A similar observation is made in the case of VP-2 and VP-3 (Figure 5(e) and (f)). In the case of knowlesipains, the compounds interacted mainly with S2 residues (Figure 5(g) and (h)). A comparison to a recent study using novel artemisinin derivatives as FP-2 inhibitors by Liu et al., shows that the aa interactions pattern between CPG, CPH and CPI and FP-2 and FP-3 were similar (Liu et al., 2012).

Figure 5. Binding modes of CPG, CPH and CPI compounds in the binding pocket of human cathepsins and *plasmodial* homologues. Surface view of the orientation of CPG (blue), CPH (magenta) and CPI (green) on the S1 (pale yellow), S2 (cyan), S3 (brick-red) and S1' (orange) of (a) Cat K, (b) Cat L, (c) FP-2, (d) FP-3, (e) VP-2, (f) VP-3, (g) KP-2) and (h) KP-3.




3.4. Stability of protein–ligand (CP) complexes

10 ns all-atom MD simulation of each of the proteases in complex with the CP derivatives was performed to obtain a dynamical picture of the conformational changes as a function of time. For quality assurance, the convergence of thermodynamic parameters namely temperature, total and potential energies was performed beforehand (data not shown). To determine if the simulated protein–ligand system formed stable complexes, the root mean square deviation (RMSD), a global measure of conformational diversity, the radius of gyration (Rg), a measure of compactness and the root mean square fluctuation (RMSF), a local measure of conformational diversity relative to the initial structures, were monitored. Using an in house Perl script, the mean and standard deviations of RMSD for the apo structures, CPs and protein–CP complexes as well as the Rg during the last 6 ns of MD simulations were determined. In the first 2 ns, the RMSD values increased after which they converged.

From Figure (6(a)), resulting RMSD values of all apo structures used in this study indicated that they were quite stable based on the error bars. In Figure (6(b)), the human cathepsins-CPs attained RMSD values ranging from .15 to .19 nm with standard deviations of up to .02 nm, while the *plasmodial*-CPs complexes had RMSD values ranging from .18 up to .29 nm. The little fluctuations as depicted by the standard deviations suggested that the complexes were stable and snapshots of structures at different times could be collected for further analysis. The effect of a ligand is either to stabilize or to destabilize a receptor upon binding and thus considering the small size of CPs compared to the respective proteins used in this study and the resultant RMSD values (Figure 6(c)), all CPs compounds seemed to stabilize the systems. As seen from Figure (6(d)), during the simulation, all structures were compact. From the RMSF plots (Supplementary Figure S2), the *plasmodial* proteases (falcipains and vivapains) exhibited huge local conformational diversity within the β -hairpin (~aa 175–aa 200), an inimitable structure associated with the binding of haemoglobin (Hb) (Hogg et al., 2006). This observation was consistent with the other *plasmodial* proteases

(Data not shown). In contrast, the human cathepsins (Cat K and Cat L) exhibited minimal RMSF fluctuations, a fact linked to the much shorter arm region. All other residues showing huge fluctuations were located on loop regions. As these fluctuations were not occurring in the active site, it can be concluded that the protein–ligand complex system remained stable during the simulation period. Structure visualization using PyMOL showed the ligands fitted well onto the binding pockets and their stabilization was facilitated mostly by a network of hydrophobic and hydrogen bonding between the ligand’s atoms and residues lining the S1, S2 S3 and S1’ subsites.

Figure 6. Stability of protein–CPs complexes as determined by GROMACS tools during the last 6 ns of MD simulations. Graphs showing the mean values of RMSD for apo structures (a), protein–ligand complexes (b), ligands only (c) and the radius of gyration for protein–ligand complexes (d). Error bars show the standard deviations.




3.5. Structural chemical features of binding

Several interactions between the residues lining the active pocket subsites and the ligand play key role in stabilizing it depending on the chemical group and nature of the surrounding environment. To extract the aa–ligand-binding footprint along the MD simulations for all generated 3D structures, a Perl script with LigPlot + batch processing functionality was used. Supplementary Table S4 shows the number and individual aa involved in van der Waals interactions and hydrogen bonds, respectively. Notably, from these interaction results, the number of van der Waals and hydrogen interactions between CPD, CPE and CPF and protein residues were drastically fewer compared to when the proteins were interacting with the rest of CPs, an observation that could be explained by their observed binding modes and the short length of R1. In contrast, CPG, CPH and CPI maintained van der Waals interactions with most subsite aa residues mainly because of the extended chemical nature of R1. Figure 7 illustrates the conformational changes of compound CPG in complex with Cat K (Figure 7(a)) and FP-2 (Figure 7(b)) during MD simulations.

Table 3. Protein–CP complexes overall BFE (ΔG_{bind}) in kJ mol^{-1} as determined by *g_mmpbsa* tool.

Protein	Compound								
	CPA	CPB	CPC	CPD	CPE	CPF	CPG	CPH	CPI
FP-2	-84.9 ± .2	-71.8 ± .3	-80.8 ± .2	-91.1 ± 2.7	-93.1 ± .2	-80.5 ± .2	-131.5 ± .2	-103.4 ± .2	-99.6 ± .2
FP-3	-77.0 ± .2	-67.1 ± .2	-66.7 ± .2	-74.2 ± .2	-74.7 ± .2	-102.8 ± .4	-87.6 ± .2	-111.7 ± .2	-105.7 ± .3
VP-2	-95.0 ± .2	-78.7 ± .2	-60.6 ± .2	-85.8 ± .2	-72.4 ± .6	-77.7 ± .3	-116.2 ± .3	-81.8 ± .2	-93.0 ± .2
VP-3	-112.4 ± .2	-72.6 ± .2	-59.0 ± .5	-98.6 ± .3	-55.0 ± .2	-62.1 ± .3	-104.8 ± .2	-93.7 ± .2	-85.7 ± .2
PK-2	-115.5 ± .3	-68.8 ± .3	-68.8 ± .4	-92.8 ± .3	-99.0 ± .2	-85.7 ± .3	-129.2 ± .2	-61.9 ± .3	-86.8 ± .2
PK-3	-80.3 ± .4	-63.0 ± .2	-81.7 ± .3	-82.1 ± .2	-80.4 ± .2	-80.9 ± .2	-68.5 ± .3	-76.2 ± .3	-80.9 ± .3
BP-2	-92.9 ± .2	-92.1 ± .4	-82.8 ± .4	-133.3 ± .5	-80.5 ± .5	-85.0 ± .3	-135.4 ± .4	-131.7 ± .3	-94.9 ± .3
CP-2	-73.0 ± .2	-85.4 ± .2	-71.9 ± .1	-108.3 ± .3	-122.6 ± .3	-83.7 ± .3	-103.9 ± .4	-103.4 ± .3	-98.1 ± .3
YP-2	-91.6 ± .3	-67.0 ± .3	-82.1 ± .2	-103.0 ± .2	-114.6 ± .3	-89.1 ± .3	-92.3 ± .2	-104.8 ± .2	-97.8 ± .3
Cat S	-97.7 ± .2	-72.2 ± .2	-83.9 ± .3	-85.8 ± .3	-85.6 ± .2	-84.9 ± .3	-93.8 ± .3	-98.2 ± .3	-81.8 ± .3
Cat K	-86.4 ± .3	-91.3 ± .2	-93.6 ± .2	-90.8 ± .3	-104.1 ± .2	-76.6 ± .3	-96.3 ± .3	-80.0 ± .2	-81.8 ± .2
Cat L	-132.4 ± .3	-99.2 ± .2	-44.7 ± .5	-129.2 ± .3	-117.5 ± .2	-111.8 ± .3	-117.3 ± .3	-149.7 ± .3	-147.6 ± .2

Figure 8. Subsite amino acid contributions to BFE for compound CPG, CPH and CPI.




contributed to a net positive energy as opposed to S2 and S1' ... S2 and S3 residues contributed to negative energies for all non-human *plasmodial* proteases in complex with the three ligands (Figure 8(b) and (c)). This explains why Cat L had lower BFE value for the three ligands compared to Cat K. In the case of the *plasmodial* proteases binding, hot spots were mainly found within the binding cleft subsites. As seen in Figure (8(c)), S3 aa impaired binding of the ligands onto the *plasmodial* cysteine as opposed to the human cathepsins. This information is quite important in understanding the residues giving attractive contributions to binding and should be considered during the rational drug design process of novel *plasmodial* cysteine protease inhibitors with increased selectivity towards the human proteases.

4. Conclusion

We report a comprehensive *in silico* approach encompassing several computational methods namely homology modelling, molecular docking, MD simulations and BFE calculations to determine the broad spectrum inhibitory activity and selectivity of non-peptidic compounds against FPs and their homologues from different *Plasmodium* species and human cathepsins. Although the compounds used in this study have been tested for activity mainly against FP-2 and FP-3 via wet laboratory assays (Batra et al., 2003; Chipeleme et al., 2007; Chiyanzu et al., 2003; Coterón et al., 2010; Domínguez et al., 2005; Greenbaum et al., 2004; Kerr, Lee, Faraday et al., 2009; Li et al., 1995; Liu et al., 2001; Verissimo et al., 2008), to our knowledge this was the first attempt to report the broad spectrum inhibitory activity of these compounds using *in silico* approaches against FPs and their homologues. Through molecular docking, MD simulations and BFE calculations, key amino acids within the receptors' active pocket responsible for the strong binding of the CPs ligands were deciphered. In all cases, van der Waals forces and polar solvation energies were proposed as the main BFE terms favouring and inhibiting the binding of CPs to the receptors respectfully. CPs represents a class of non-peptidic compounds with a broad spectrum activity against *plasmodial* FP homologues. Although there was no clear cut selectivity profiles of these compounds against human cathepsins, previous pre-clinical studies involving cysteine protease inhibitors with little or no selectivity to target *trypanosomal* and *plasmodial* parasites were tolerated in animal models. This can be linked to the fact that the human cathepsins are present in elevated concentrations compared to that of the parasite origin and the redundant nature of the mammalian cysteine proteases family (Ang et al., 2011). However, besides the beneficial intracellular housekeeping roles of human cathepsins, they can also be attractive targets for drug discovery as they have been found to play specific roles in antigen presentation, bone resorption and pro-hormone activation, processes critical for the progression of a variety of disease states such as rheumatoid arthritis, osteoporosis and autoimmune maladies. Hence, this protocol may also be valuable to the identification of potential inhibitors against the human cathepsins (Figure 9).

Figure 9. Per-residue decomposition fingerprint of compound CPG, CPH and CPI in complex with (a) Cat K (b) Cat L (c) FP-2 (d) FP-3 (e) VP-2 and (f) VP-3.



A 3D-QSAR study by Cátia et al., on peptidyl vinyl sulfone derivatives as FP-2 inhibitors showed the major structural requirements necessary for optimal activity (Teixeira, Gomes, Couesnon, & Gomes, 2011). A similar approach on non-peptidic heteroarylnitrile derivatives by Wang et al., led to comparable conclusions where different subsite pockets preferred groups with certain chemical properties (Wang et al., 2013). A comparison of these results to our docking, MD and BFE shows great consistency. For example, from the per-residue energy decomposition, key aa contributing to the BFE of F2-CPI, a total of 10 residue including Asp35, Cys42, Leu84, Val152, Ser153, Asp154, Asp155, Asn173, His174 and Ala175 were identified in both cases as important in the binding process. The consideration of the important players (energetics and residues) in binding of non-peptidic compounds to proteases of key human *Plasmodium* species as well as the human cathepsins presents unique results that can be exploited in the structure-based molecular guided design of more potent antimalarial drugs.

List of abbreviations

3D-QSAR	Three-dimensional quantitative structure–activity relationship
ACPYPE	AnteChamber PYthon Parser interfacE
BFE	Binding free energy
BP-2	Bergheipain-2
Cat L	Cathepsin L
Cat K	Cathepsin K
Cat S	Cathepsin S
CP-2	Chabaudipain-2
CPs	5-substituted-2-cyanopyrimidines
FP	Falcipain
GROMACS	GRONingen MACHine for Chemical Simulations
KP	Knowlesipain

MD	Molecular dynamics
MM-PBSA	Molecular mechanics–Poisson–Boltzmann surface area
RMSD	Root mean square deviation
RMSF	Root mean square fluctuation
VP	Vivapain
WHO	World Health Organization
YP	Yoeliipain

Acknowledgements

The authors greatly acknowledge CHPC for providing access to the cluster computational facility for MD simulations and BFE calculations. Special thanks to Dane Kennedy (Bioinformatics Application Scientist, CHPC) for his technical assistance in compiling the required software onto the cluster system. The original LigPlot+ batch-processing script was written by Ricardo Ferreira of University of Lisbon. TMM and AMK thank Rhodes University for postgraduate scholarships.

Disclosure statement

No potential conflict of interest was reported by the authors.

References

- Ang, K. K. H., Ratnam, J., Gut, J., Legac, J., Hansell, E., Mackey, Z. B., ... Renslo, A. R. (2011). Mining a cathepsin inhibitor library for new antiparasitic drug leads. *PLoS Neglected Tropical Diseases*, *5*, e1023. doi:10.1371/journal.pntd.0001023
- Ashley, E., McGready, R., Proux, S., & Nosten, F. (2006). Malaria. *Travel medicine and infectious disease*, *4*, 159–173. doi:10.1016/j.tmaid.2005.06.009
- Aurrecoechea, C., Brestelli, J., Brunk, B. P., Dommer, J., Fischer, S., Gajria, B., ... Wang, H. (2009). PlasmoDB: A functional genomic database for malaria parasites. *Nucleic Acids Research*, *37*(Database), D539–D543. doi:10.1093/nar/gkn814
- Batra, S., Sabnis, Y. A., Rosenthal, P. J., & Avery, M. A. (2003). Structure-based approach to falcipain-2 inhibitors: Synthesis and biological evaluation of 1,6,7-trisubstituted dihydroisoquinolines and isoquinolines. *Bioorganic & Medicinal Chemistry*, *11*, 2293–2299. doi:10.1016/S0968-0896(03)00117-2
- Benkert, P., Biasini, M., & Schwede, T. (2011). Toward the estimation of the absolute quality of individual protein structure models. *Bioinformatics*, *27*, 343–350. doi:10.1093/bioinformatics/btq662
- Benkert, P., Tosatto, S. C. E., & Schomburg, D. (2008). QMEAN: A comprehensive scoring function for model quality assessment. *Proteins*, *71*, 261–277. doi:10.1002/prot.21715

Bernstein, F. C., Koetzle, T. F., Williams, G. J., Meyer, E. F., Brice, M. D., Rodgers, J. R., ... Tasumi, M. (1977). The protein data bank: A computer-based archival file for macromolecular structures. *Journal of Molecular Biology*, *112*, 535–542. Retrieved from [http://www.ncbi.nlm.nih.gov/pubmed/87503210.1016/S0022-2836\(77\)80200-3](http://www.ncbi.nlm.nih.gov/pubmed/87503210.1016/S0022-2836(77)80200-3)

Bussi, G., Donadio, D., & Parrinello, M. (2007). Canonical sampling through velocity rescaling. *The Journal of Chemical Physics*, *126*, 014101. doi:10.1063/1.2408420

Centre for High Performance Computing. (n.d.). Retrieved October 22, 2014, from <http://www.chpc.ac.za/>

Chipeleme, A., Gut, J., Rosenthal, P. J., & Chibale, K. (2007). Synthesis and biological evaluation of phenolic Mannich bases of benzaldehyde and (thio)semicarbazone derivatives against the cysteine protease falcipain-2 and a chloroquine resistant strain of *Plasmodium falciparum*. *Bioorganic & Medicinal Chemistry*, *15*, 273–282. doi:10.1016/j.bmc.2006.09.055

Chiyanzu, I., Hansell, E., Gut, J., Rosenthal, P. J., McKerrow, J. H., & Chibale, K. (2003). Synthesis and evaluation of isatins and thiosemicarbazone derivatives against cruzain, falcipain-2 and rhodesain. *Bioorganic & Medicinal Chemistry Letters*, *13*, 3527–3530. doi:10.1016/S0960-894X(03)00756-X

Coterón, J. M., Catterick, D., Castro, J., Chaparro, M. J., Díaz, B., Fernández, E., ... Fiandor, J. M. (2010). Falcipain inhibitors: optimization studies of the 2-pyrimidinecarbonitrile lead series. *Journal of Medicinal Chemistry*, *53*, 6129–6152. doi:10.1021/jm100556b

Crooks, G., Hon, G., Chandonia, J., & Brenner, S. (2004). WebLogo: A sequence logo generator. *Genome Research*, *14*, 1188–1190. doi:10.1101/gr.849004.1

Desai, P. V., & Avery, M. A. (2004). Structural characterization of vivapain-2 and vivapain-3, cysteine proteases from *Plasmodium vivax*: Comparative protein modeling and docking studies. *Journal of Biomolecular Structure & Dynamics*, *21*, 781–790. doi:10.1080/07391102.2004.10506968

Domínguez, J. N., León, C., Rodrigues, J., Gamboa de Domínguez, N., Gut, J., & Rosenthal, P. J. (2005). Synthesis and evaluation of new antimalarial phenylurenyl chalcone derivatives. *Journal of Medicinal Chemistry*, *48*, 3654–3658. doi:10.1021/jm058208o

Eddy, S. R. (2004). Where did the BLOSUM62 alignment score matrix come from? *Nature Biotechnology*, *22*, 1035–1036. doi:10.1038/nbt0804-1035

Ehmke, V., Rottman, M., Brun, R., Schirmeister, T., Diederich, F. F., Heindl, C., & Stich, A. (2011). Potent and selective inhibition of cysteine proteases from *Plasmodium falciparum* and *Trypanosoma brucei*. *Abstracts of Papers of the American Chemical Society*, *242*, 273–278. doi:10.1002/cmdc.201000449

Ettari, R., Bova, F., Zappala, M., Grasso, S., Micale, N., & Zappalà, M. (2010). Falcipain-2 inhibitors. *Medicinal Research Reviews*, *30*, 136–167. doi:10.1002/med.20163

- Flexner, C., Bate, G., & Kirkpatrick, P. (2005). Tipranavir. *Nature Reviews. Drug Discovery*, 4, 955–956. doi:10.1038/nrd1907
- Greenbaum, D. C., Mackey, Z., Hansell, E., Doyle, P., Gut, J., Caffrey, C. R., ... Chibale, K. (2004). Synthesis and structure–activity relationships of parasiticidal thiosemicarbazone cysteine protease inhibitors against *Plasmodium falciparum*, *Trypanosoma brucei*, and *Trypanosoma cruzi*. *Journal of Medicinal Chemistry*, 47, 3212–3219. doi:10.1021/jm030549j
- Gnuplot (4.6.6) [Computer software]. <http://gnuplot.sourceforge.net/>
- Gupta, S., Jadaun, A., Kumar, H., Raj, U., Varadwaj, P. K., & Rao, A. R. (2015). Exploration of new drug-like inhibitors for serine/threonine protein phosphatase 5 of *Plasmodium falciparum*: A docking and simulation study. *Journal of Biomolecular Structure & Dynamics*, 33, 2421–2441. doi:10.1080/07391102.2015.1051114
- Hartjes, L. B. (2011). Preventing and detecting malaria infections. *The Nurse Practitioner*, 36, 45–53. doi:10.1097/01.NPR.0000397912.05693.20
- Hatherley, R., Blatch, G. L., & Tasthan Bishop, O. (2014). Plasmodium falciparum Hsp70-x: A heat shock protein at the host-parasite interface. *Journal of Biomolecular Structure & Dynamics*, 32, 1766–1779. doi:10.1080/07391102.2013.834849
- Hess, B., Bekker, H., Berendsen, H. J. C., & Fraaije, J. G. E. M. (1997). LINCS: A linear constraint solver for molecular simulations. *Journal of Computational Chemistry*, 18, 1463–1472. doi:10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H.
- Hogg, T., Nagarajan, K., Herzberg, S., Chen, L., Shen, X., Jiang, H., ... Schmidt, C. L. (2006). Structural and functional characterization of Falcipain-2, a hemoglobinase from the malarial parasite *Plasmodium falciparum*. *Journal of Biological Chemistry*, 281, 25425–25437. doi:10.1074/jbc.M603776200
- Kato, K., Misawa, K., Kuma, K., & Miyata, T. (2002). MAFFT: A novel method for rapid multiple sequence alignment based on fast Fourier transform. *Nucleic Acids Research*, 30, 3059–3066. doi:10.1093/nar/gkf436
- Kerr, I. D., Lee, J. H., Farady, C. J., Marion, R., Rickert, M., Sajid, M., ... Brinen, L. S. (2009). Vinyl sulfones as antiparasitic agents and a structural basis for drug design. *Journal of Biological Chemistry*, 284, 25697–25703. doi:10.1074/jbc.M109.014340; 10.1074/jbc.M109.014340
- Kerr, I. D., Lee, J. H., Pandey, K. C., Harrison, A., Sajid, M., Rosenthal, P. J., & Brinen, L. S. (2009). Structures of falcipain-2 and falcipain-3 bound to small molecule inhibitors: Implications for substrate specificity. *Journal of Medicinal Chemistry*, 52, 852–857. doi:10.1021/jm8013663
- Kollman, P. A. (1996). Advances and continuing challenges in achieving realistic and predictive simulations of the properties of organic and biological molecules. *Accounts of Chemical Research*, 29, 461–469. doi:10.1021/ar9500675

Kumar, A., Kumar, K., Korde, R., Puri, S. K., Malhotra, P., & Singh Chauhan, V. (2007). Falcipain-1, a *Plasmodium falciparum* cysteine protease with vaccine potential. *Infection and Immunity*, *75*, 2026–2034. doi:10.1128/IAI.01533-06

Kumari, R., Kumar, R., & Lynn, A. (2014). g_mmpbsa-A GROMACS tool for high-throughput MM-PBSA calculations. *Journal of Chemical Information and Modeling*, *54*, 1951–1962. doi:10.1021/ci500020m

Langhorne, J., Buffet, P., Galinski, M., Good, M., Harty, J., Leroy, D., ... Duffy, P. (2011). The relevance of non-human primate and rodent malaria models for humans. *Malaria Journal*, *10*, 25697–25703.

Laskowski, R. A., MacArthur, M. W., Moss, D. S., & Thornton, J. M. (1993). PROCHECK: A program to check the stereochemical quality of protein structures. *Journal of Applied Crystallography*, *26*, 283–291. doi:10.1107/S0021889892009944

Laskowski, R. A., & Swindells, M. B. (2011). LigPlot+: Multiple ligand–protein interaction diagrams for drug discovery. *Journal of Chemical Information and Modeling*, *51*, 2778–2786. doi:10.1021/ci200227u

Lee, B. J., Singh, A., Chiang, P., Kemp, S. J., Goldman, E. A., Weinhouse, M. I., ... Rosenthal, P. J. (2003). Antimalarial activities of novel synthetic cysteine protease inhibitors. *Antimicrobial Agents and Chemotherapy*, *47*, 3810–3814. Retrieved from <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=296233&tool=pmcentrez&rendertype=abstract>10.1128/AAC.47.12.3810-3814.2003

Li, R., Kenyon, G. L., Cohen, F. E., Chen, X., Gong, B., Dominguez, J. N., ... McKerrow, J. H. (1995). *In Vitro* antimalarial activity of chalcones and their derivatives. *Journal of Medicinal Chemistry*, *38*, 5031–5037. doi:10.1021/jm00026a010

Liu, M., Wilairat, P., & Go, M.-L. (2001). Antimalarial alkoxyated and hydroxylated chalcones: Structure–activity relationship analysis. *Journal of Medicinal Chemistry*, *44*, 4443–4452. doi:10.1021/jm0101747

Liu, Y., Lu, W.-Q., Cui, K.-Q., Luo, W., Wang, J., & Guo, C. (2012). Synthesis and biological activities of novel artemisinin derivatives as cysteine protease falcipain-2 inhibitors. *Archives of Pharmacal Research*, *35*, 1525–1531. doi:10.1007/s12272-012-0902-4

Mane, U. R., Gupta, R. C., Nadkarni, S. S., Giridhar, R. R., Naik, P. P., & Yadav, M. R. (2013). Falcipain inhibitors as potential therapeutics for resistant strains of malaria: A patent review. *Expert Opinion on Therapeutic Patents*, *23*, 165–187. doi:10.1517/13543776.2013.743992

Marco, M., & Miguel Coteron, J. (2012). Falcipain inhibition as a promising antimalarial target. *Current Topics in Medicinal Chemistry*, *12*, 408–444. doi:10.2174/156802612799362913

Marvin, Calculator Plugin and Chemical Terms Demo « ChemAxon – cheminformatics platforms and desktop applications. (n.d.). Retrieved October 22, 2014, from

<http://www.chemaxon.com/marvin/sketch/index.php>Melnikova, I. (2008). Hepatitis C therapies. *Nature Reviews Drug Discovery*, 7, 799–800. doi:10.1038/nrd2661

Melo, F., Devos, D., Depiereux, E., & Feytmans, E. (1997). ANOLEA: A www server to assess protein structures. *Proceedings / ... International Conference on Intelligent Systems for Molecular Biology; ISMB. International Conference on Intelligent Systems for Molecular Biology*, 5, 187–190. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/9322034>[PubMed]

Mendis, K., Sina, B. J., Marchesini, P., & Carter, R. (2001). The neglected burden of *Plasmodium vivax* malaria. *The American Journal of Tropical Medicine and Hygiene*, 64(1–2 Suppl), 97–106. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/11425182>

Mok, S., Imwong, M., Mackinnon, M. J., Sim, J., Ramadoss, R., Yi, P., ... Bozdech, Z. (2011). Artemisinin resistance in *Plasmodium falciparum* is associated with an altered temporal pattern of transcription. *BMC Genomics*, 12, 391. doi:10.1186/1471-2164-12-391

Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009). Software news and updates AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. *Journal of Computational Chemistry*, 30, 2785–2791. doi:10.1002/jcc.21256

O'Boyle, N. M., Banck, M., James, C. A., Morley, C., Vandermeersch, T., & Hutchison, G. R. (2011). Open Babel: An open chemical toolbox. *Journal of Cheminformatics*, 3, 33. <http://www.jcheminf.com/content/3/October/2011>

Pandey, K. C., & Dixit, R. (2012). Structure-function of falcipains: Malarial cysteine proteases. *Journal of Tropical Medicine*, 2012, 345195. doi:10.1155/2012/345195

Parrinello, M. (1981). Polymorphic transitions in single crystals: A new molecular dynamics method. *Journal of Applied Physics*, 52, 7182–7190.

Pei, J., & Grishin, N. V. (2007). PROMALS: Towards accurate multiple sequence alignments of distantly related proteins. *Bioinformatics*, 23, 802–808. doi:10.1093/bioinformatics/btm017

Pei, J., Kim, B. H., & Grishin, N. V. (2008). PROMALS3D: A tool for multiple protein sequence and structure alignments. *Nucleic Acids Research*, 36, 2295–2300. doi:10.1093/nar/gkn072

Petersen, H. G. (1995). Accuracy and efficiency of the particle mesh Ewald method. *The Journal of Chemical Physics*, 103, 3668–3679.

Pronk, S., Pall, S., Schulz, R., Larsson, P., Bjelkmar, P., Apostolov, R., ... Lindahl, E. (2013). GROMACS 4.5: A high-throughput and highly parallel open source molecular simulation toolkit. *Bioinformatics*, 29, 845–854. doi:10.1093/bioinformatics/btt055

Prugnolle, F., Durand, P., Ollomo, B., Duval, L., Arieu, F., Arnathau, C., ... Renaud, F. (2011). A fresh look at the origin of *Plasmodium falciparum*, the most malignant malaria agent. *PLoS Pathogens*, 7, e1001283. doi:10.1371/journal.ppat.1001283

Rosenthal, P. J. (2011). Falcipains and other cysteine proteases of malaria parasites. *Advances in Experimental Medicine and Biology*, 712, 30–48. doi:10.1007/978-1-4419-8414-2_3

Rosenthal, P. J., Lee, G. K., & Smith, R. E. (1993). Inhibition of a *Plasmodium vinckei* cysteine proteinase cures murine malaria. *Journal of Clinical Investigation*, 91, 1052–1056. doi:10.1172/JCI116262

Rosenthal, P. J., Wollish, W. S., Palmer, J. T., & Rasnick, D. (1991). Antimalarial effects of peptide inhibitors of a *Plasmodium falciparum* cysteine proteinase. *Journal of Clinical Investigation*, 88, 1467–1472. doi:10.1172/JCI115456

Sabnis, Y. A., Desai, P. V., Rosenthal, P. J., & Avery, M. A. (2003). Probing the structure of falcipain-3, a cysteine protease from *Plasmodium falciparum*: Comparative protein modeling and docking studies. *Protein Science*, 12, 501–509. doi:10.1110/ps.0228103

Saralamba, S., Pan-Ngum, W., Maude, R. J., Lee, S. J., Tarning, J., Lindegardh, N., ... White, L. J. (2011). Intrahost modeling of artemisinin resistance in *Plasmodium falciparum*. *Proceedings of the National Academy of Sciences*, 108, 397–402. doi:10.1073/pnas.1006113108

Sayers, E. W., Barrett, T., Benson, D. A., Bryant, S. H., Canese, K., Chetvernin, V., ... Ye, J. (2009). Database resources of the National Center for Biotechnology Information. *Nucleic Acids Research*, 37(Database), D5–D15. doi:10.1093/nar/gkn741

Schulz, F., Gelhaus, C., Degel, B., Vicik, R., Heppner, S., Breuning, A., ... Schirmeister, T. (2007). Screening of protease inhibitors as antiplasmodial agents. Part I: Aziridines and epoxides. *ChemMedChem*, 2, 1214–1224. doi:10.1002/cmdc.200700070

Shen, M.-Y., & Sali, A. (2006). Statistical potential for assessment and prediction of protein structures. *Protein Science*, 15, 2507–2524. doi:10.1110/ps.062416606

Soding, J., Biegert, A., & Lupas, A. N. (2005). The HHpred interactive server for protein homology detection and structure prediction. *Nucleic Acids Research*, 33(Web Server), W244–W248. doi:10.1093/nar/gki408

Sousa da Silva, A. W., & Vranken, W. F. (2012). ACPYPE – AnteChamber PYthon Parser interfacE. *BMC Research Notes*, 5, 367. doi:10.1186/1756-0500-5-367

Teixeira, C., Gomes, J. R. B., Couesnon, T., & Gomes, P. (2011). Molecular docking and 3D-quantitative structure activity relationship analyses of peptidyl vinyl sulfones: *Plasmodium Falciparum* cysteine proteases inhibitors. *Journal of Computer-Aided Molecular Design*, 25, 763–775. doi:10.1007/s10822-011-9459-4

Teixeira, C., Gomes, J. R. B., & Gomes, P. (2011). Falcipains, *Plasmodium falciparum* cysteine proteases as key drug targets against malaria. *Current Medicinal Chemistry*, 18, 1555–1572. doi:10.2174/092986711795328328

Thillainayagam, M., Pandian, L., Murugan, K. K., Vijayaparthasarathi, V., Sundaramoorthy, S., Anbarasu, A., & Ramaiah, S. (2014). *In silico* analysis reveals the anti-malarial potential of quinolinyl chalcone derivatives. *Journal of Biomolecular Structure and Dynamics*, *33*, 961–977. doi:10.1080/07391102.2014.920277

Tina, K. G., Bhadra, R., & Srinivasan, N. (2007). PIC: Protein interactions calculator. *Nucleic Acids Research*, *35*(Web Server), W473–W476. doi:10.1093/nar/gkm423

Verissimo, E., Berry, N., Gibbons, P., Cristiano, M. L. S., Rosenthal, P. J., Gut, J., ... O'Neill, P. M. (2008). Design and synthesis of novel 2-pyridone peptidomimetic falcipain 2/3 inhibitors. *Bioorganic & Medicinal Chemistry Letters*, *18*, 4210–4214. doi:10.1016/j.bmcl.2008.05.068

Wang, J., Li, F., Li, Y., Yang, Y., Zhang, S., & Yang, L. (2013). Structural features of falcipain-3 inhibitors: An *in silico* study. *Molecular BioSystems*, 2296–2310. doi:10.1039/c3mb70105k

Wang, S. X., Pandey, K. C., Scharfstein, J., Whisstock, J., Huang, R. K., Jacobelli, J., ... McKerrow, J. H. (2007). The structure of chagasin in complex with a cysteine protease clarifies the binding mode and evolution of an inhibitor family. *Structure*, *15*, 535–543. doi:10.1016/j.str.2007.03.012

Waterhouse, A. M., Procter, J. B., Martin, D. M. A., Clamp, M., & Barton, G. J. (2009). Jalview Version 2 – A multiple sequence alignment editor and analysis workbench. *Bioinformatics*, *25*, 1189–1191. doi:10.1093/bioinformatics/btp033

World Health Organization (WHO) (2013) *World malaria report 2013*. Retrieved June 22, 2014, from http://www.who.int/malaria/publications/world_malaria_report_2013/wmr2013_no_profiles.pdf?ua=1

Zhao, B., Janson, C. A., Amegadzie, B. Y., D'Alessio, K., Griffin, C., Hanning, C. R., ... Abdel-Meguid, S. S. (1997). Crystal structure of human osteoclast cathepsin K complex with E-64. *Nature Structural Biology*, *4*, 109–111. doi:10.1038/nsb0297-109

Supplementary material

Figure S1: Homology models of all plasmodial homologs together with the template structures (2OUL and 3BWK). Structure parts coloured blue depict correctly modelled parts while red show poorly modelled portions.





Figure S2: RMSF graphs of the different proteins in complex with CPs.



Text S1: Amino acid sequences of Falcipain-2 and its homologs (*plasmodial* proteases and human cathepsins)

Plasmodial cysteine proteases

>PF3D7_1115700 (Falcipain-2)

MDYNMDYAPHEVISQQGERFVVDKYVDRKILKNKSLLLVILSVLSVVGFLFYFTPNRKSDFKNSSVENNNDYIINSL
KSPNGKKFIVSKIDEALSFYDSKKNNDINKYNEGNNNNADFKGLSLFKENTPSNNFIHNKDYFINFFDNKFLMNAEHINQFY
MFIKTNNKQYNSPNEMKERFQVFLQNAHKVNMHNNNNKNSLYKKELNRFADLTYHEFKNKYLSLRSSKPLKNSKYLQDQMN
VVIKYYKGNENFDHAAAYDWRHLHSGVTPVKDQKNCGSCWAFSSIGSVESQYAIRKNKLITLSEQELVDCSFKNYGCGNGLINNAF
EDMIELGGICTDDDYPIVSDAPNLCNIDRCKTEKYGIKNYLSVPDNKLEALRFLGPISSISAVSDDFAFYKEGIFDGECDQL
NHAVMLVGFGMKEIVNPLTKKGEKHYYYIIKNSWGWQWGERGFINIEETDESGLMRKCGLTDAFIPLIE

>PF3D7_1115400 (Falcipain-3)

MEYHMEYSPNEVIKQEREVFGKEKSGSKFKRKRISIFIVLTVSICFMFALMLFYFTRNENKTLFTNSLSNNINDYIINSL
KSESGKKFIVSKLEELISSYDKEKKMRTTGAEENNMNMGIDDKDNKSVFVNKKNGLKVNNNNQVSYSNLFDTKFLMDNLE
TVNLFYIFLKENNKYETSEEMQKRFILFSENYRKIELHNKKTNSLYKRGMNKFGDLSPEEFRSKYLNKTHGPFKTLSPV
YEANYEDVIKKYKPADAKLDRIAYDWRHLHGGVTPVKDQALCGSCWAFSSVGSVESQYAIRKALFLFSEQELVDCSVKNGCY
GGYITNAFDDMIDLGLCSQDDYPYVSNLPEETCNLRCNERYTIKSYVSIIPDDKFKEALRYLGPISISIAASDDFAFYRGGFY
DGECAAPNHAIVLVGYGMKDIYNEDTGRMEKFFYYYIIKNSWGSWEGGYINLETDENGYKKTCSIGTEAYVPLLE

>PVX_091415 (Vipapain-2)

MEYHIEYASNEGKSEKEAFVQNSFSQTNKGKRGKLLVFLVSAICLLAGSAFYFTRTGKESDGPLYGNALDESSDDFIIT
LLKSPGGKKFIVSKLTELVASYDKDGNSSQEEKHSGELTTEERSEKGEHYYKRFGNLKIISKSEINFADAKFLMTNLESVN
FYLFVKEYGRKYKTEEMQQRYLAFVENLEKIKAHNSRENVLYRKGMMQFQDLSFGEFKKYLTLSKSFDFKTFGGKLRITNY
EDVIDKYKPKDATFDHASYDWRHLHKGVTVPVKDQANCSCWAFSTVGVVSESQYAIRKNQLVSISEQQMVDCSTQNTGCGYGF
LAFEDMIEMGGLCSSEDPYVADIPEMCKFDICEQKYIINNLEIPEDKFKEAIRFLGPLSVSIAVSDDFAFYRGGIFDGECC
EAPNHAIVLVGFGAEDAYDFDTKTMKRYYYIVKNSWGVSWGEGKGFIRLETINGYRKPCLGTEALVALVD

>PVX_091410 (Vivapain-3)

MDYHMQYNAQDPINGERKGFVGGYIDKAILKKNKCLILLSVSAICIFVCSAFYFTRPAKRDRGGVYKIDKVDDDDYINFL
LKSNGKKFIVSKVQELISTYDVKKENLPAQHGGTYKRFKAKRDQCTRNNCSVSPYGNAAQVEVVAQVNLVNLVDTKFLMAN
LETVNSFYLFMKEHGKEYSTADEMQRYLSFAENLAKIKAHNSRENVLYRKGMMRFGDLSFEEIKKYLTLKSFDLKSDGKIS
PRVSDYDDI IHKYKPKDGTDFDYVKHDWREFNAVTPVKDQKNCGACWAFSTVGVVSESQYAIRKELVSLSEQEMVDCSFKNYGC
DGGNIPAFEDLLDLGGICEKEYPYVDVTPPELCDIDRCKNKYKITTYVEIPQLRFKEAIKFLGPI SVSICANDDFVYEGGL
FDGSCGFSNHAIVLVGYGMEEMYDAMSRKNEKRYFVWLNKSWGEGWEGKGYMKIQTDEYGLMKTCSLGAQAFVALIDEV

>PCHAS_091190 (Chaubapain-2)

MNYHSSHIRPEEEMFVDKGIQNRARLRKKNQMLIVTLAIVLSMFGFTVIYFNKTNKSSFNNLNVQNSNDDYILINYLKSKVVK
KFMGSKIIEELIVSEKNAKNANI VKNANDEHNKNYKKTPLFKNNNDGKKFSANLYDMKFIMSNLESVNIYFNFMKKFNKQYN
SAEEMQERFYIFTENLKKVEKHNEKKYMYKGINPFSMDRPEEFKMRYLNSKLESTIIDLRHLIPYSAISKYKSPDTKVN
YKSFDRWHNAIIAVKQKRCASCWAFATAGVIEAQYAIRQNKIISLSEQQLVDCSQNNDGCEGGILPYAFEDLIDMGLCED
KYYPYVADVPELCEINKCKEYTAIEYALVPYDNYKEAIQYLGPLTIAVGAASEDFQDYDGGIFDGEECTGFANHAIVLVGYGVE
SVFDESLLKKNVDQYYYIIRNSWSDAWGEEGYMRLKTDESAGLRNCVQLVQAYVPIIE

>PKH_091250 (Knowpain-3)

MEYHVQYNTQEPINAEKKTFLGQGYIDKTFRLKKNKNSLILLSVSAICIFVCSAFYFTRTSNTDGGITYQIADNVDDDDYVINF
LKSNGKKFIVSKVQELISTYSKDKENTSTQNGGIFKRFKSNKAGNCSVGPYRMNATEVQTVQAYLQNLIDAKFLMTN
LENVNSFYLFIKEHGKQYTPDEMQRHLSFVENLAKINAHNNKENVSYKGMNRFQDMSFEEFEKKYLTLLKTFDFKSNGLKS
TRFISYDDVIHKYKPKDGTDFDYVKHDWRELNAVTPVKDQKNCGACWAFSTVGVVSESQYAIRKNELVSLSEQEMVDCSFKNNGC
DGGLIPRAFEDMIEMGGLCKGKEYPYVDVTPPELICYIDRCKKYYKVTAYVEVPQVRFKEAIKFLGPI SVSINANDDFTYEGGL
FDGSCSISPNAHAIVLVGYGMEAMYDAMSRQYKRYYYLLRNSWGEKWEKGYMKIQTDEFGLLKTCDLGEAYVALIEE

>PKH_091260 (Knowpain-2)

MEYQVEYTSNDSAKSEKEAFVQNSYNQTNKGRRRFLVLSVAAICLVAGSAFYFTRTEKTNDNNSDDVIINTLLKSPGGKK
FIISKLTELVASYDKEGNLQEQKPSNELISFVDRNEKSEENFRKRFGNLKNKKIVDINFADSRFLMTNLENVNSFYLFIKEH
GKKYQTPDEMQRHLSFVENLAKINAHNNKENVSYKGMNRFQDMSFEEFEKKYLTLLKTFDFKSNGLKSTQLISYDDVINRYK
PKDDKFDHTKYDWRHLHRGVTVPVKDQDQCGSCWAFSTVGVVSESQYLIRKNELVSISEQQMVDCSLQNNCGDGGFIPRALEDIE
MKGLCSTEAYPYGVEVPEKCKYDMCDRKYINSFFEIEPEFKFKEAVRYLGPISVNI AVSDDFAFYQGGIFNGECGRRTTNAHVI
LVGFGAEDVYSDMNTTRKRYYYIIKNSWGVSWGERGFIRMETDINGYRKPCLLGLAFAFVGLVE

>PBANKA_093240 (Berghepain-2)

MNYHSSHIRPEEIEFVDKGIQNVQLRRKNKMLIVTLAIVLGMFGFTVIYFNRTNKSSFNNGNVENYSNDDYILINYLKSKAV
KFMGSKIEELIVSEQNEKNSIIVKDNKNNDYNEKSVLFNKNNDKSF'TNLHDMQSIMNLESVNIYFNFMKEYNKQYNSA
EIQERFYIFSENKKEIKHNKENHLYTKGINAFSDMRHEEFKMKYLNKLNKLNHNSIDLRLHIPYTTAISKYKSPDTKVNYS

FDWRDYNVIIGVKDQQKCASCWAFATAGVVAQAQYAIRKNQKVSLSLSEQQLVDCAQNNFGCEGGILPYAFEDLIDMDGLCEDKYY
PYVSNVPELCEINKCTEKYSISKFALVPFNKYKAIQYLGPIITIAVGVDDDFESYNGGIFDGECTDFANHAVMLIGYGVVEEYV
DKRLKKNVKEYYYYIRNSWGEDWGERGYIRLKTNESGTLRNCVVLVQGYAPIIE

>PY00783 (Berghepains-2)

MNYHSSHHIRPEEEIFVDKGIQNVQLRRKNKMLIVTLAIVLSMFGFTVIYFNKTKSSFNNGNVENYSNDDYLINYLKSKAV
KKFMGSKIEELIVESEKNEKNENNSVVVKDNKNNKDNNEKNVLFNKNTDNKKFTANLHDMQSIMNNLESVNLFYFMMKKYNKE
YSSAEMQERFYIFSEKLLKIEKHKNENHLYTKGINAFSDMRHEEFKMKYLNNKLKENHQIDLRHLIPYITAINKYKSPDQI
NYTSFDWRDHNAIIDIKDQQKCASCWAFATAGVVAQAQYAIRKNQKVSLSLSEQQLVDCAQNNFGCDGGILPYAFEDLIDMNGLCE
DKYYPYVSNLPELCEINKCQEKYTIKSFALVPFNKYKAIQYLGPIITIAVGVADDFESYSGGIFDGECTSYANHAVMLIGYGV
EDVYDIHLQKYVKEYYYYIRNSWGEFWEHGYMRLKTNELGTLRNCVVLVQGYAPIIE

Human cathepsins

>gi|157830076 (Cathepsin K)

APDSVDYRKKGYVTPVKNQGCQSCWAFSSVGALEGQLKKKTGKLLNLSLQNLVDCVSENDGCGGGYMTNAFQYVQKNRGIDS
EDAYPYVQEEESCMYNPTGKAAKCRGYREIPEGNEKALKRAVARVGPVSVVAIDASLTSFQFYKGVVYDESCNSDNLNHAFLA
VGYGIQKGNKHWIKNSWGENWGNKGYILMARNKNNACGIANLASFPKM

>gi|313754424 (Cathepsin L)

EAPRSVDWREKGYVTPVKNQGCQSCWAFSATGALEGQMFRTGRLISLSEQNLVDCSGPQNEGCNGGLMDYAFQYVQDNGG
LDSEESYPYEATEESCKYNPKYSVANDTGFVDIPKQEKALMKAVATVGPISVAIDAGHESFLFYKEGIYFEPDCSSEDMDHG
LVVGYGFESTESDNNKYWLKNSWGEWGMGGYVMAKDRRNHCGIASAASYPTV

>gi|30749675 (Cathepsin S)

LPDSVDWREKGCVTVEVKYQSCGACWAFSAVGALEAQLKLTGKLVTLQAQNLVDCSTEKYGNKGCNGGFMTAFQYIIDNKG
IDSDASYPKAMDQKQYDSKYRAATCSKYTELPGREDVLKEAVANKGPVSVGV DARHPSFFLYRSGVYVYEPDCTQNVNHGV
LVVGYGDLNGKEYWLKNSWGHNFGEEGYIRMARNKGNHCGIASFSPYPEI

Table S1: List of databases and webservers used for obtaining data sets and analysis

Website	Address
PlasmoDB	http://plasmodb.org/plasmo/
NCBI BLAST	http://blast.ncbi.nlm.nih.gov/
MAFFT Online Server	http://mafft.cbrc.jp/alignment/server/
PROMALS3D	http://prodata.swmed.edu/promals3d/promals3d.php
WebLogo	http://weblogo.berkeley.edu/logo.cgi
HHpred Online Server	http://toolkit.tuebingen.mpg.de/hhpred
RCSB Protein Data Bank	http://www.rcsb.org/pdb/home/home.do
MetaMQAPII	https://genesilico.pl/toolkit/unimod?method=MetaMQAPII
ANOLEA	http://swissmodel.expasy.org/workspace/
ProSA	https://prosa.services.came.sbg.ac.at/prosa.php
Protein Interaction Calculator	http://pic.mbu.iisc.ernet.in/index.html

Table S2. A summary of template protein identified by HHpred webserver and their corresponding percentage sequence identities

FP homolog	Template	% Sequence Identity	E-value
VP-2	FP-2	63	$3.3e^{-66}$
	FP-3	67	$2.7e^{-70}$
CP-2	FP-2	50	$1.5e^{-64}$
	FP-3	49	$5.8e^{-65}$
KP-2	FP-2	56	$3.9e^{-67}$
	FP-3	58	$1.7e^{-68}$
BP-2	FP-2	52	$4.7e^{-64}$
	FP-3	48	$1.3e^{-65}$
YP-2	FP-2	49	$1.7e^{-63}$
	FP-3	48	$4.3e^{-66}$
VP-3	FP-2	57	$4.3e^{-67}$
	FP-3	58	$5.6e^{-69}$
KP-3	FP-2	57	$5.5e^{-66}$
	FP-3	60	$1.1e^{-67}$

Table S3. Homology models validation scores as predicted by Modeller, PROCHECK and MetaMQAPII

Model	Template	Dope Z-score	PROCHECK (%)^a	GDT-TS (%)
BP-2	2OUL	-0.9	87.0	60.5
			12.0	
			0.5	
			0.5	
CP-2	2OUL	-0.9	86.0	63.8
			12.0	
			0.9	
			0.5	
KP-2	3BWK	-1.0	91.0	63.4
			7.0	
			0.9	
			0.9	
KP-3	2OUL-3BWK	-1.3	92.0	69.1
			7.5	
			0.5	
			0.0	
VP-2	2OUL-3BWK	-1.3	87.0	65.4
			9.0	
			0.5	
			0.9	
VP-3	2OUL-3BWK	-1.0	87.0	64.6
			10.0	
			0.9	
			0.4	
YP-2	2OUL	-0.8	89.0	63.6
			9.0	
			0.5	
			0.9	

^aPercentage values corresponding to number of residues located in the most favoured, additionally allowed, generously allowed regions and disallowed regions respectively.

Table S4: Interaction profiles of CPs and FP-2/3 and homologs at different time steps during MD simulations. HBR and VDR indicate the individual aa involved in hydrogen (HBR) and number of aa participating in van der Waals (VDR) interactions respectively

Protein	Compound											
	Time (ns)	Type	CPA	CPB	CPC	CPD	CPE	CPF	CPG	CPH	CPI	
Cathepsin S	0	HBR	Q19,N163	Q19,C22	Q19	0	Q19,G20	G20	Q19	Q19	Q19,D96	
		VDR	13	11	11	6	5	4	10	11	13	
	2	HBR	N163	W186	0	G20	A140	0	N67	0	0	
		VDR	15	9	7	4	6	5	9	10	10	
	4	HBR	N163	0	0	Q19,G20	Q19	0	0	W186	W186	
		VDR	13	9	7	4	5	5	10	13	12	
	6	HBR	N163	Q19,W186	0	0	0	0	N67	W186	0	
		VDR	16	9	11	2	3	5	12	12	14	
	8	HBR	N163	Q19,W186	0	0	0	W186	0	0	W186	G69
		VDR	17	10	5	3	6	4	12	13	13	
	10	HBR	G69,N163	0	0	0	W186	0	Q19,N67	W186	0	
		VDR	16	9	9	4	4	2	13	12	13	
	Cathepsin L	0	HBR	G69,D163	0	0	G62	G62	G69	G69,D163	G69,D163	G69,D163
			VDR	13	13	11	4	4	4	15	13	15
2		HBR	D163	0	0	G62	G68	G62	0	G69,D163	G69,D163	
		VDR	10	3	5	5	3	3	17	15	17	
4		HBR	G69,D163	N19,G21	N19	G62	G69	G62	D163	G69,D163	D163	
		VDR	13	8	7	4	2	5	16	16	16	
6		HBR	D163	0	0	0	G62	G62	0	G69,D163	D163	
		VDR	10	8	2	3	5	6	13	17	16	
8		HBR	D163	0	E193	0	G62	G68,G69	G69,D163	G69,D163	G69,D163	
		VDR	11	8	3	4	4	6	15	17	15	
10		HBR	G69,D163	0	E193	0	G69,Y73	G68,G69	D163	G69,D163	G69,D163	
		VDR	11	8	4	3	4	5	17	15	18	
Cathepsin K		0	HBR	Y67	0	G66	G66,N161	Y67	G66	G66	G19	G66
			VDR	14	13	16	5	3	5	16	13	12
	2	HBR	0	G66	0	0	0	G66,Y67	W26	0	N161	
		VDR	8	12	11	3	4	4	12	7	8	
	4	HBR	0	G66	0	G65	G65	G64	0	0	0	
		VDR	8	12	9	6	4	4	10	10	9	
	6	HBR	0	G66	L160	0	G65	0	W26	0	0	
		VDR	8	12	10	4	4	3	12	10	10	
	8	HBR	0	G66	L160	Y67,L160	G66,Y67	G64	W26,Y67	0	N161	
		VDR	7	13	11	3	3	1	7	13	10	
	10	HBR	L160	G66,N161	L160	Y67,L160	0	0	W26	0	0	
		VDR	11	12	8	4	4	2	8	10	8	
	Falcpain-2	0	HBR	G83,N173	G83,N173	G83,N173	N81,G83	Q36,C42,N81	G83	G40	G83,N173	G83,N173
			VDR	14	17	16	7	6	3	16	14	15

	2	HBR	N173	N173	N173	N173,C42,N81, G83,H174	N38,C39,C80	G83	N173	N173	N173	
		VDR	13	12	9	9	6	0	15	12	12	
	4	HBR	G40,N173	N173	N173	G40,C42	0	G83,L84	G83,N173	N173	N173	
		VDR	14	13	13	6	5	5	13	13	12	
	6	HBR	N173	N173	N173	G40,G83,N173	Q36,N38	0	G83	N173	N173	
		VDR	11	13	12	9	4	3	15	14	12	
	8	HBR	G40,N173	0	N173	0	C80	N81	G83	N173	N173	
		VDR	13	6	11	5	5	6	14	16	13	
	10	HBR	G40,N173	0	N173	0	C39	0	G83,N173	G83,N173	N173	
		VDR	13	8	9	8	6	4	13	13	17	
Falcipain-3	0	HBR	C44,N175	0	0	0	0	A39	0	0	0	
		VDR	15	12	14	Q38,W208	3	6	9	9	9	
	2	HBR	N175	0	0	0	0	C41	0	L40	W208	
		VDR	9	8	8	4	6	5	7	8	13	
	4	HBR	N175	0	0	0	0	L40	N175	L40	Q38	
		VDR	13	11	9	4	3	1	11	11	13	
	6	HBR	N175	0	0	0	0	0	N75	L40	Q38,W208	
		VDR	10	10	9	4	3	1	11	9	11	
	8	HBR	G85,N175	0	0	0	0	0	N175	L40	W208	
		VDR	11	11	7	3	1	5	10	11	10	
	10	HBR	N175	Q38	0	0	N175	0	0	L40	Q38	
		VDR	10	12	11	1	1	7	10	10	11	
	Vivapain-2	0	HBR	G84,N174	G84,N174	0	G83,G84	Y82	G41,Y82	N174	Y82,G84	Y82
			VDR	14	12	10	3	3	4	17	15	16
2		HBR	N174	G84,N174	0	G84	Y82	0	N174	0	Y82	
		VDR	13	12	8	3	4	3	16	11	14	
4		HBR	N174	G84,N174	G83,N173	Y82	0	0	G84,N174	0	Y82	
		VDR	10	14		1	4	G41,Y82	16	6	14	
6		HBR	N174	N174		Y82	0	0	N174	Y82	N174	
		VDR	13	9		3	5	3	8	12	5	
8		HBR	Q37,N174	G84,N174		G84	0	C81	G84,N174	Y82	N174	
		VDR	16	14		2	2	5	16	10	10	
10		HBR	N174	N174		0	0	0	N174	0	N174	
		VDR	14	12		4	2	5	15	7	10	
Vivapain-3	0	HBR	Q36,W206	N173	0	0	0	K37	D81,G83	0	G83,N173	
		VDR	12	13	9	3	5	3	16	14	16	
	2	HBR	Q36	N173	N173	0	0	0	D81	D81,G83	0	G83,N173
		VDR	16	10	10	2	3	2	13	10	19	
	4	HBR	Q36	N173	0	0	0	0	D81	G83	N153,N173	N173
		VDR	13	12	14	4	3	3	16	13	16	
	6	HBR	Q36,C42,W206	G40,N173	G84	0	0	0	D81,G83	N173	N173	
		VDR	16	11	8	1	4	6	16	12	10	
	8	HBR	Q36	G40,N173	0	0	0	0	D81	N173	N173	
		VDR	15	10	6	3	3	7	13	13	12	
	10	HBR	Q36,W206	N173	0	C43,G84,N174,H175	K37	0	0	0	N173	

		VDR	15	9	10	8	4	3	12	7	11	
Knowlesipain-2	0	HBR	C43	0	N174,W207	W207	0	0	Q37,C40	Q37,T158	G84,T158,N174	
		VDR	15	14	11	4	5	4	16	14	18	
		HBR	0	0	Q37	0	N39,N174	0	0	Q37,C43	0	N174
	2	VDR	10	8	9	6	6	1	14	10	14	
		HBR	0	0	Q37	Q37,K38,H175	N39,N174	0	0	Q37,C43	0	N174
	4	VDR	11	8	5	5	7	4	13	12	11	
		HBR	0	0	Q37	0	N39,N174,W207	0	0	Q37,W207	S150	N174
	6	VDR	11	7	6	3	6	4	14	12	12	
		HBR	0	0	N174	K38	N174	0	0	Q37	0	N174
	8	VDR	11	10	11	7	6	2	14	12	13	
		HBR	0	G41,G83	Q37	0	K38,C40,N174,W207	T158	0	Q37,C43,W207	D82	N174
	10	VDR	9	14	9	3	8	3	14	12	10	
		HBR	C38,G82,N172	0	N172	N172	G39,G82	G82	G82	N172	N172	
	Knowlesipain-3	0	VDR	17	12	10	3	5	4	12	14	13
HBR			N172	N172	N172	N172	0	0	N172	0	N172	
2		VDR	13	12	13	4	4	2	13	12	15	
		HBR	N172	N148,N172	N172	0	G82	D80	N172	N172	N172	
4		VDR	10	13	14	5	3	3	15	9	15	
		HBR	N172	0	G82,N172	N172	D80	D80	N172	N172	N172	
6		VDR	11	16	8	4	3	1	11	9	13	
		HBR	N172	0	N172	G82,N172	G82	D80	N172	N172	N172	
8		VDR	12	14	10	4	2	4	12	13	12	
		HBR	N172	N148,N172	N172	T79	G82	G82	N172	N172	N172	
10		VDR	16	15	12	5	3	3	14	9	11	
		HBR	Q38	Q37,C40	W207	C43,N174	C43,N174	A41	Q37	Q37,H175	G84	
Berghepain-2		0	VDR	11	10	13	6	7	5	14	12	14
			HBR	Q38	Q37,C40	E82	H175	D154	0	Q37,W207	Q37,W207	W207
	2	VDR	8	8	10	6	4	4	13	10	15	
		HBR	Q38	Q37,C40	E82	N174,H175	C43,N174	0	W207	Q37,W207	W207	
	4	VDR	10	9	12	4	4	5	12	14	11	
		HBR	Q38	C40	E82	A41	0	0	Q37	Q37,W207	0	
	6	VDR	11	6	10	7	3	6	11	13	11	
		HBR	Q38	C40	0	C40	0	G84	W207	Q37,W207	0	
	8	VDR	10	8	8	4	3	3	13	12	11	
		HBR	Q38	0	G84	C43,G84	0	G84	W207	Q37,W44,W207	0	
	10	VDR	10	9	8	8	2	3	11	10	9	
		HBR	0	Q37	Q158,W207	A41,G84,N174	C43,G84,N174	A41	0	G84,N174	N174	
	Chabaupain-2	0	VDR	14	9	14	6	8	6	15	14	15
			HBR	0	Q37,C40	W207	N174	A41,N174	A41	0	N174	Q158,N174
2		VDR	8	8	8	8	6	6	14	11	14	
		HBR	0	Q37,C40	0	0	H175	0	0	N174	N174	
4		VDR	9	9	12	5	7	2	9	11	15	
		HBR	0	Q37,C40	0	A41,N174	N174,H175	Q158	Q37	N174	N174	
6		VDR	6	8	7	6	5	4	11	12	14	
		HBR	0	C40	Q37	N174	C43,H175	E168	Q37	N174	N174	

		VDR	8	9	5	6	5	4	12	12	13
	10	HBR	0	0	Q37	W207	C43,H175	E155	Q37,E155,T170	N174	N174
		VDR	6	7	6	3	5	4	10	12	14
Yoelipain-2	0	HBR	N174	0	0	C43,N174,H175	0	0	G84,N174	G84,N174	G84
		VDR	12	13	14	7	7	2	13	18	13
	2	HBR	N174	G84	G84	0	A41,N174	G84,A173	Q37,N174	G84,N174	N174
		VDR	12	6	8	3	8	4	14	12	14
	4	HBR	G84,N174	G84	0	0	0	A173	N174	N174	N174
		VDR	9	7	6	4	8	5	10	14	14
	6	HBR	N174	0	0	A41,N174	0	0	N174	N174	N174
		VDR	12	8	10	3	8	4	11	12	12
	8	HBR	N174	0	0	0	0	G84	G84,N174	N174	N174
		VDR	12	9	9	7	7	6	13	10	13
	10	HBR	N174	0	0	0	A41,C43,W207	G84	N174	G84,N174	N174
		VDR	10	9	8	0	5	5	12	12	13

Table S5: Individual binding free energy terms in kJ/mol as determined by molecular mechanics Poisson-Boltzmann surface area analysis. vdW=van der Waals forces, ele=electrostatics, PB=polar solvation energy, SASA=Soluble Accessible Surface Area, bind=binding free energy

Protein	Energy	Compound								
		CPA	CPB	CPC	CPD	CPE	CPF	CPG	CPH	CPI
Cat S	ΔG_{vdW}	-178.1±0.3	-130.4±0.2	-138.9±0.3	-138.7±0.3	-134.2±0.3	-121.2±0.3	-163.8±0.3	-197.4±0.2	-164.9±0.2
	ΔE_{ele}	-22.3±0.1	-30.8±0.1	-31.0±0.1	-22.3±0.1	-26.9±0.2	-14.4±0.1	-36.7±0.2	-36.0±0.2	-33.3±0.2
	ΔG_{PB}	122.0±0.3	104.4±0.3	101.0±0.3	90.3±0.2	91.2±0.4	64.7±0.3	125.5±0.4	157.9±0.4	134.9±0.3
	ΔG_{SASA}	-19.1±0.03	-15.4±0.03	-15.0±0.03	-15.1±0.01	-15.6±0.03	-14.0±0.03	-18.7±0.02	-22.7±0.02	-18.5±0.02
	ΔG_{bind}	-97.7±0.2	-72.2±0.2	-83.9±0.3	-85.8±0.3	-85.6±0.2	-84.9±0.3	-93.8±0.3	-98.2±0.3	-81.8±0.3
Cat K	ΔG_{vdW}	-136.0±0.3	-156.2±0.2	-151.1±0.2	-129.3±0.2	-160.1±0.2	-151.1±0.3	-172.5±0.3	-131.6±0.2	-148.5±0.2
	ΔE_{ele}	-1.3±0.2	-3.9±0.2	-15.5±0.2	0.8±0.1	-19.7±0.1	-8.3±0.1	-12.0±0.2	-36.8±0.2	20.1±0.2
	ΔG_{PB}	66.6±0.3	85.2±0.2	89.2±0.2	52.7±0.2	93.5±0.2	100.3±0.3	108.7±0.4	103.6±0.2	62.9±0.2
	ΔG_{SASA}	-15.7±0.02	-16.3±0.02	-16.2±0.02	-15.0±0.02	-17.8±0.02	-17.4±0.03	-20.5±0.03	-15.2±0.02	-16.3±0.03
	ΔG_{bind}	-86.4±0.3	-91.3±0.2	-93.6±0.2	-90.8±0.3	-104.1±0.2	-76.6±0.3	-96.3±0.3	-80.0±0.2	-81.8±0.2
Cat L	ΔG_{vdW}	-150.9±0.3	-119.5±0.3	-77.4±0.5	-156.9±0.2	-141.4±0.2	-143.8±0.2	-176.8±0.3	-203.3±0.2	-200.1±0.2
	ΔE_{ele}	-46.3±0.1	-25.9±0.2	-29.0±0.4	23.4±0.2	-2.8±0.1	1.7±0.2	-26.8±0.3	-51.4±0.1	-46.3±0.1
	ΔG_{PB}	80.6±0.2	60.5±0.4	69.0±0.5	68.5±0.3	43.0±0.3	48.0±0.3	107.0±0.2	126.1±0.2	119.8±0.2
	ΔG_{SASA}	-15.8±0.02	-14.1±0.03	-10.2±0.04	-17.3±0.02	-16.3±0.02	-17.7±0.02	-20.7±0.02	-21.1±0.02	-21.0±0.02
	ΔG_{bind}	-132.4±0.3	-99.2±0.2	-44.7±0.5	-129.2±0.3	-117.5±0.2	-111.8±0.3	-117.3±0.3	-149.7±0.3	-147.6±0.2
FP-2	ΔG_{vdW}	-150.6±0.2	-128.2±0.3	-132.3±0.2	-150.0±2.7	-140.9±0.2	-132.3±0.2	-194.3±0.2	-167.0±0.2	-183.6±0.2
	ΔE_{ele}	-44.2±0.2	-21.4±0.2	-29.5±0.1	-20.9±1.7	-12.6±0.1	-11.8±0.1	-44.5±0.1	-38.1±0.1	-39.4±0.1
	ΔG_{PB}	127.4±0.3	93.1±0.3	96.5±0.2	95.0±3.1	75.3±0.2	79.7±0.3	127.8±0.2	121.3±0.2	144.3±0.2
	ΔG_{SASA}	-17.4±0.02	-15.2±0.02	-15.5±0.02	-15.2±0.40	-15.0±0.02	-16.1±0.02	-20.5±0.02	-19.6±0.02	-20.9±0.01
	ΔG_{bind}	-84.9±0.2	-71.8±0.3	-80.8±0.2	-91.1±2.7	-93.1±0.2	-80.5±0.2	-131.5±0.2	-103.4±0.2	-99.6±0.2
FP-3	ΔG_{vdW}	-158.0±0.2	-125.1±0.2	-120.7±0.1	-120.0±0.2	-113.9±0.3	-153.3±0.6	-153.4±0.3	-150.4±0.2	-191.0±0.3
	ΔE_{ele}	-33.3±0.1	-25.9±0.2	-28.9±0.1	-2.2±0.1	-6.7±0.1	-16.0±0.1	-23.0±0.1	-34.3±0.1	-28.8±0.2
	ΔG_{PB}	133.0±0.2	98.6±0.3	95.9±0.2	62.6±0.3	60.2±0.4	82.2±0.4	107.3±0.4	90.5±0.3	134.7±0.3
	ΔG_{SASA}	-18.9±0.02	-14.7±0.03	-13.0±0.02	-14.6±0.02	-14.2±0.03	-15.8±0.04	-18.5±0.03	-17.6±0.02	-20.6±0.02
	ΔG_{bind}	-77.0±0.2	-67.1±0.2	-66.7±0.2	-74.2±0.2	-74.7±0.2	-102.8±0.4	-87.6±0.2	-111.7±0.2	-105.7±0.3
VP-2	ΔG_{vdW}	-161.1±0.2	-143.7±0.2	-95.3±0.2	-137.6±0.3	-90.7±0.4	-170.5±0.3	-191.3±0.2	-128.1±0.2	-160.1±0.3
	ΔE_{ele}	-29.0±0.1	-37.4±0.1	-14.1±0.1	-15.2±0.1	-9.3±0.4	-6.0±0.1	-39.6±0.1	-12.1±0.2	-10.1±0.1
	ΔG_{PB}	113.3±0.2	119.2±0.2	62.4±0.2	83.7±0.3	40.0±0.5	117.4±0.3	136.0±0.2	74.2±0.3	96.8±0.2
	ΔG_{SASA}	-18.1±0.02	-16.8±0.01	-13.4±0.03	-16.8±0.03	-12.4±0.04	-18.8±0.02	-21.3±0.02	-15.8±0.03	-19.6±0.02
	ΔG_{bind}	-95.0±0.2	-78.7±0.2	-60.6±0.2	-85.8±0.2	-72.4±0.6	-77.7±0.3	-116.2±0.3	-81.8±0.2	-93.0±0.2
VP-3	ΔG_{vdW}	-187.1±0.2	-135.7±0.2	-146.6±0.3	-145.4±0.2	-96.6±0.2	-104.4±0.3	-185.1±0.2	-62.8±0.2	-174.0±0.2
	ΔE_{ele}	-30.7±0.2	-35.2±0.1	-19.0±0.4	-32.0±0.2	-9.6±0.1	-12.4±0.2	-42.3±0.1	-28.5±0.1	-22.7±0.1

	ΔG_{PB}	124.5±0.2	114.6±0.2	124.0±0.5	94.2±0.3	63.0±0.3	68.0±0.5	143.1±0.3	116.1±0.2	131.1±0.2
	ΔG_{SASA}	-19.2±0.02	-16.3±0.02	-17.3±0.03	-15.4±0.01	-11.9±0.02	-13.3±0.03	-20.5±0.02	-18.6±0.01	-20.1±0.02
	ΔG_{bind}	-112.4±0.2	-72.6±0.2	-59.0±0.5	-98.6±0.3	-55.0±0.2	-62.1±0.3	-104.8±0.2	-93.7±0.2	-85.7±0.2
PK-2	ΔG_{vdW}	-164.8±0.2	-99.7±0.2	111.5±0.2	-147.8±0.5	-169.3±0.2	-126.8±0.2	-217.1±0.2	-143.8±0.2	-162.9±0.2
	ΔE_{ele}	-16.7±0.1	-9.3±0.2	-25.1±0.3	-22.0±0.2	28.0±0.1	-21.6±0.1	-50.6±0.1	-38.7±0.2	-36.4±0.1
	ΔG_{PB}	82.8±0.2	51.8±0.4	-82.0±0.4	93.2±0.5	117.0±0.2	78.0±0.3	161.6±0.3	138.4±0.3	13.0±0.2
	ΔG_{SASA}	-16.8±0.02	-11.7±0.03	-14.1±0.03	-16.3±0.04	-18.8±0.01	-15.2±0.02	-23.1±0.02	-17.8±0.02	-20.5±0.02
	ΔG_{bind}	-115.5±0.3	-68.8±0.3	-68.8±0.4	-92.8±0.3	-99.0±0.2	-85.7±0.3	-129.2±0.2	-61.9±0.3	-86.8±0.2
PK-3	ΔG_{vdW}	-143.0±0.2	-146.8±0.1	-158.1±0.2	-143.2±0.3	-148.5±0.2	-157.0±0.2	-148.7±0.2	-148.0±0.2	-145.2±0.2
	ΔE_{ele}	-34.1±0.2	-25.9±0.2	-18.8±0.3	-26.7±0.2	-15.7±0.2	-24.0±0.1	-27.1±0.1	-30.5±0.1	-33.4±0.1
	ΔG_{PB}	114.7±0.3	127.2±0.2	113.2±0.2	104.0±0.4	101.1±0.2	118.3±0.2	125.4±0.4	120.1±0.5	118.6±0.4
	ΔG_{SASA}	-18.0±0.02	-17.5±0.01	-18.1±0.01	-16.2±0.03	-17.2±0.01	-18.2±0.02	-18.1±0.03	-18.0±0.02	-20.9±0.02
	ΔG_{bind}	-80.3±0.4	-63.0±0.2	-81.7±0.3	-82.1±0.2	-80.4±0.2	-80.9±0.2	-68.5±0.3	-76.2±0.3	-80.9±0.3
BP-2	ΔG_{vdW}	-151.3±0.2	-138.3±0.2	-125.2±0.3	-166.8±0.5	-103.4±0.4	-136.7±0.4	-176.6±0.3	-183.3±0.2	-155.7±0.3
	ΔE_{ele}	-32.7±0.1	-31.8±0.3	-17.2±0.2	-30.5±0.2	-12.5±0.3	-9.0±0.2	-44.3±0.2	-54.0±0.1	-8.7±0.2
	ΔG_{PB}	106.8±0.2	93.2±0.4	73.6±0.3	81.3±0.3	48.0±0.5	76.7±0.3	104.4±0.5	125.3±0.3	90.0±0.3
	ΔG_{SASA}	-15.6±0.02	-15.2±0.01	-14.0±0.03	-17.4±0.03	-12.6±0.04	-16.0±0.03	-19.0±0.03	-19.7±0.02	-20.1±0.02
	ΔG_{bind}	-92.9±0.2	-92.1±0.4	-82.8±0.4	-133.3±0.5	-80.5±0.5	-85.0±0.3	-135.4±0.4	-131.7±0.3	-94.9±0.3
CP-2	ΔG_{vdW}	-115.4±0.2	-146.5±0.2	-148.6±0.1	-171.5±0.2	-185.0±0.2	-130.1±0.3	-135.9±0.3	-150.7±0.3	-173.3±0.2
	ΔE_{ele}	-2.3±0.1	-26.3±0.2	-17.5±0.2	-19.6±0.2	-15.8±0.1	-5.1±0.2	-43.4±0.4	-32.1±0.2	-32.2±0.2
	ΔG_{PB}	60.2±0.3	103.6±0.3	112.3±0.2	100.5±0.4	96.8±0.2	66.1±0.3	93.4±0.2	96.8±0.3	128.3±0.3
	ΔG_{SASA}	-15.5±0.03	-16.3±0.02	-18.2±0.01	-17.7±0.02	-18.6±0.02	-14.7±0.02	-18.1±0.02	-17.3±0.03	-20.9±0.02
	ΔG_{bind}	-73.0±0.2	-85.4±0.2	-71.9±0.1	-108.3±0.3	-122.6±0.3	-83.7±0.3	-103.9±0.4	-103.4±0.3	-98.1±0.3
YP-2	ΔG_{vdW}	-161.0±0.2	-100.3±0.3	-132.1±0.4	-159.3±0.2	-166.0±0.2	-137.4±0.3	-168.8±0.3	-167.1±0.2	-175.1±0.3
	ΔE_{ele}	-32.8±0.1	12.6±0.2	-19.4±0.1	-13.8±0.1	-19.1±0.2	-2.2±0.2	-28.9±0.2	-52.1±0.1	-30.4±0.2
	ΔG_{PB}	121.6±0.2	34.4±0.4	85.5±0.3	87.6±0.2	87.4±0.2	67.0±0.2	125.6±0.4	134.9±0.3	128.6±0.3
	ΔG_{SASA}	-19.4±0.02	-13.6±0.02	-16.2±0.03	-17.4±0.01	-17.0±0.02	-16.5±0.02	-20.2±0.02	-20.4±0.02	-20.8±0.02
	ΔG_{bind}	-91.6±0.3	-67.0±0.3	-82.1±0.2	-103.0±0.2	-114.6±0.3	-89.1±0.3	-92.3±0.2	-104.8±0.2	-97.8±0.3

Table S6. Decomposition of BFE for each of the complexes (Protein-CPs) into individual amino acid residue contributions. Only aa residues with $|\Delta G| \geq 2.0$ kcal/mol are listed

Protein	CPA	CPB	CPC	CPD	CPE	CPF	CPG	CPH	CPI
Cat S	Gly23 -3.3	Tyr18 -2.4	Tyr18 -2.7	Cys22 -4.1	Tyr18 -3.8	Tyr18 -3.0	Gly20 3.8	Tyr18 -2.5	Gly20 2.3
	Cys25 -2.4	Gly20 2.8	Gln19 -2.3	Gly23 -3.1	Gly20 2.5	Gly20 2.5	Cys22 -4.1	Gly20 3.2	Cys22 -2.3
	Trp26 -2.4	Cys22 -4.2	Gly20 3.2	Ala140 2.8	Cys22 -2.5	Ala140 2.1	Gly23 -2.3	Cys25 -2.1	Phe70 -2.9
	Lys64 -2.3	Gly23 -2.9	Cys22 -5.1	Phe146 -3.6	Phe146 -3.1	Phe146 -5.0	Asn67 -2.6	Phe70 -3.5	Phe146 -3.6
	Gly69 2.7	Phe146 -3.2	Gly23 -2.5	Trp186 -10.2	Trp186 -8.6	Trp186 -12.4	Asp96 3.2	Arg141 4.9	Trp186 -10.5
	Gly70 -5.5	Trp186 -10.2	Ala140 2.5				Phe146 -3.5	Phe146 -4.1	
	Arg141 5.1		Phe146 -3.1				Trp186 -9.6	Asn163 3.1	
	Asn163 -4.9		Trp186 -12.6					Trp186 -15.4	
	His164 -2.2								
Gly165 -2.4									
Cat L	Lys18 3.1	Asp138 -2.4	Asn19 2.0	Lys18 2.9	Lys18 2.4	Lys18 2.8	Lys18 3.3	Lys18 2.8	Lys18 2.9
	Gln20 2.4	Leu145 -5.2	Glu192 2.6	Gln20 2.3	Glu36 -2.1	Glu36 -2.4	Glu36 -2.8	Gln20 2.5	Gln20 2.3
	Glu36 -2.8	Asp163 -3.2	Glu193 9.5	Glu36 -2.7	Glu51 -3.7	Glu51 -4.2	Glu51 -4.7	Cys26 -2.3	Cys26 -2.4
	Glu51 -4.9	Trp190 -11.5		Glu51 -4.6	Asp56 -2.0	Asp56 -2.1	Asp56 -2.5	Trp27 -2.7	Trp27 -2.2
	Asp56 -2.9	Trp194 -2.1		Asp56 -2.4	Glu64 -4.4	Asn63 -2.1	Glu64 -2.8	Glu36 -2.6	Glu36 -2.5
	Glu64 -6.7			Glu64 -4.0	Gly69 -2.5	Glu64 -3.8	Leu70 -3.9	Glu51 -4.3	Glu51 -4.3
	Asn67 -2.1			Asn67 -2.4	Leu70 -7.4	Gly69 -3.2	Asp138 -5.1	Asp56 -2.5	Asp56 -2.5
	Leu70 -5.4			Gly69 -4.2	Asp72 -4.7	Leu70 -9.5	Glu142 -2.2	Glu64 -5.2	Glu64 -5.3
	Met71 -3.1			Leu70 -8.5	Glu96 -2.3	Asp72 -4.7	Leu145 -2.6	Leu70 -4.6	Leu70 -4.5
	Asp72 -2.1			Asp72 -3.8	Asp115 -2.3	Glu96 -3.1	Glu154 -2.1	Met71 -3.4	Met71 -3.4
	Glu96 -4.8			Glu96 -3.5	Lys118 3.8	Asp115 -2.7	Asp161 -4.9	Glu96 -3.6	Glu96 -3.3
	Asp138 -5.8			Lys118 2.2	Glu120 -2.1	Lys118 3.3	Asp163 15.7	Asp138 -5.2	Asp138 -5.2
	Asp161 -5.7			Asp138 -4.7	Asp138 -4.9	Glu120 -2.0	His164 -3.1	His141 -2.7	His141 -2.7
	Asp163 -8.3			Glu160 -2.2	Glu160 -3.1	Asp138 -4.9	Gly165 -2.4	Glu142 -4.8	Glu142 -4.5
	His164 -4.0			Asp161 -4.3	Asp161 -4.9	Glu160 -3.0	Lys187 3.5	Leu145 -4.9	Leu145 -4.9
	Gly165 -2.0			Met162 2.7	Asp163 -2.8	Asp161 -5.3	Glu193 -3.3	Glu154 -2.4	Glu154 -2.4
	Lys187 3.2			Asp163 -5.2	His164 -2.8	Asp163 4.2		Asp161 -4.7	Asp161 -3.6
				His164 -2.9	Lys187 2.3	Lys187 2.5		His164 -5.0	Met162 -2.4
				Lys187 3.0		Trp190 2.5		Gly165 -2.8	Asp163 2.1
								Lys187 3.2	His164 -4.9
								Gly165 -2.9	
								Lys187 3.3	
Cat K	Glu59 -2.5	Lys17 2.8	Cys63 -2.8	Glu59 -3.4	Lys17 2.1	Gly20 -3.1	Glu59 -4.0	Lys17 3.3	Glu59 -3.3
	Gly65 -4.4	Ser24 -5.2	Gly65 -6.8	Gly65 -5.4	Ser24 -2.7	Gly64 2.6	Gly62 2.8	Gly20 -3.9	Gly65 -5.7

	Ala134 -3.1 Asn156 -2.8 Asn159 -4.3 Leu160 -2.3	Glu59 -2.1 Cys63 -5.1 Gly65 -4.0 Ala134 -2.9 Asn156 -2.0 Leu160 -2.9 Asn161 -2.7	Ala134 -3.0 Asn156 -3.3 Ser157 6.4 Asn159 -4.3 Leu160 -2.3 Asn161 -2.0	Ala134 -3.4 Asn159 -2.3 Ala207 -3.0	Glu59 -2.6 Gly62 -2.0 Cys63 -4.8 Gly64 -2.6 Gly65 -5.0 Ala134 -2.8 Asn156 -2.4 Asn159 4.1 Asn161 -2.3	Ala134 -2.2 Asp158 2.7 Leu160 -2.3 Asn182 -2.3	Cys63 -2.3 Gly65 -4.5 Ala134 -4.6 Asn156 -3.1 Asn159 -2.7 Leu160 -2.5 Asn161 -2.3	Gln21 -2.6 Glu59 -3.4 Gly91 -2.9	Ala134 -3.5 Asn159 -3.8 Leu160 -2.6
FP-2	Asp35 -2.1 Gly40 3.4 Trp43 2.1 Glu67 -2.8 Cys80 2.3 Leu84 -5.2 Asn173 -3.8 His174 -3.6 Ala175 -2.2 Lys203 2.2 Asp234 3.6	Asn81 2.2 Leu84 -6.1 Asn173 2.2	Asp35 -2.4 Gln36 2.5 Glu67 -2.2 Gly83 2.7 Leu84 -4.5 Asp154 -2.3 Asn173 -2.7 His174 -3.0 Ala175 -2.1	Asp35 -2.6 Gly40 3.1 Cys42 -4.6 Val152 -2.4 Asp154 -2.2 His174 -5.5 Trp206 -3.7	Lys37 2.4 Cys39 -4.9 Gly40 -2.6 Asp154 -2.0 Asn173 4.1 Trp206 -6.2	Leu84 -5.5 His174 -2.1	Asp35 -2.5 Gln36 2.0 Cys42 -2.6 Glu67 -2.2 Leu84 -4.9 Val152 -3.5 Asp154 -3.5 Leu172 -4.4 His174 -4.1 Ala175 -2.8	Asp35 -2.8 Gln36 2.5 Glu67 -2.4 Gly83 2.9 Leu84 -3.8 Val152 -3.4 Asp154 -3.6 Asn173 -2.6 His174 -3.2 Ala175 -2.2	Asp35 -2.4 Gln36 3.3 Gly40 4.4 Cys42 -5.1 Cys80 3.2 Asn81 3.1 Gly83 3.7 Leu84 -3.4 Val152 -3.1 Ser153 -3.0 Asp154 -4.5 Asp155 -2.2 Asn173 -2.7 His174 -3.6 Ala175 -3.0
FP-3	Asp37 -3.4 Gln38 3.8 Gly42 5.0 Cys44 -3.5 Glu69 -2.4 Gly85 2.3 Tyr86 -2.5 Asp156 -2.8 Asn175 3.0 His176 -2.5 Ala177 -2.6	Asp37 -2.6 Gln38 2.8 Glu69 -2.0 Asp156 -4.5 Asp157 -2.6 Glu169 -2.2 Asn175 2.6 Trp208 -2.5	Asp37 4.3 Ala39 2.5 Cys41 -2.9 Ser43 -2.3 Asp156 -3.1 Asp157 -2.2 Arg162 2.7 Trp208 -6.2 Asp211 -3.1	Ala159 -3.6 Arg162 7.9 Trp208 -7.5 Asp211 -2.6	Gln38 3.3 Asp156 -3.4 Asp157 -2.3 Arg162 5.8 Trp208 -7.8 Asp211 -2.6	Cys44 -2.8 Ala159 -2.0 Asn175 2.8 His176 -5.2 Trp208 -5.1	Asp37 -3.1 Gln38 4.0 Gly42 2.7 Glu69 -2.0 Tyr83 2.3 Asp156 -2.7 Asp157 -3.3 Ala159 -2.8 Arg162 7.6 His176 -2.3 Trp208 -4.8 Asp211 -3.5	Leu40 -9.0 Cys41 -6.1 Gly42 -3.0 Trp208 -5.4	Asp37 2.9 Gln38 -2.9 Leu40 -6.4 Ala154 -2.2 Ala159 -2.6 Arg162 3.2 Asn175 2.8 His176 -3.9 Trp208 -9.3
VP-2	Asp36 -2.3 Ala38 2.0 Cys40 -2.2	Asp36 -2.3 Gln37 2.5 Asn39 2.3	Tyr82 -2.1 Phe85 -2.7 Val153 -2.1	Phe85 -5.5 Val153 -2.3 Asn174 3.2	Tyr82 -3.6 Phe85 -6.3 Leu88 -2.1	Asp36 -2.2 Gln37 2.1 Gly41 -3.7	Asp36 -2.2 Gln37 2.2 Cys43 -3.8	Ala38 2.2 Gly41 -2.7 Tyr82 -2.2	Asp36 -2.4 Ala38 2.0 Gly41 -2.8

	Cys43 -3.2 Glu68 -2.4 Gly84 4.6 Pro173 2.3 Asn174 -3.8 His175 -4.1 Ala176 -2.5	Glu68 -2.7 Gly84 4.2 Pro173 2.9 Asn174 -4.4 His175 -3.4	Asp155 -3.0	His175 -2.2		Glu68 -2.4 Gly84 4.6 Phe85 -2.1 Asp155 -2.0 Asn174 3.0 His175 -4.2 Ala176 -3.1 Lys204 2.1 Glu235 7.4	Glu68 -2.5 Gly84 4.3 Val153 -2.9 Ala158 -2.3 Pro173 2.6 Asn174 -6.4 His175 -5.4 Ala176 -2.4 Trp207 -2.9	Asp110 -3.5 Trp207 -3.0	Glu68 -2.2 Asp110 -3.0 Trp207 -3.4
VP-3	Asp35 4.4 Gln36 -5.0 Gly40 -2.9 Cys42 -4.6 Asp81 -2.1 Asp154 -2.1 Asn173 5.3 His174 -4.9 Trp206 -4.4	Asp35 -2.6 Gln36 2.9 Lys37 2.0 Gly40 3.0 Glu67 -2.6 Cys80 2.1 Gly83 4.5 Asn173 -3.7 His174 -3.6 Lys209 2.6	Asp35 -3.4 Gln36 6.9 Gly40 4.9 Cys42 -3.1 Glu67 -2.6 Cys80 3.3 Asp81 4.5 Gly83 2.4 Asp154 -2.2 His174 -3.5 Ala175 -2.1 Lys209 2.3	Asn38 3.3 Cys39 -5.2 Gly40 -4.6 Cys42 -2.3 Asp81 -4.2 Val157 -3.0 Asn173 3.3 His174 -3.2 Trp206 -9.1 Lys209 2.3	Asp35 4.0 Gln36 3.7 Asp81 -2.7 Val157 -3.7 Trp206 -10.6 Lys209 3.7	Gln36 2.7 Asn38 2.3 Val157 -3.6 Trp206 -3.2 Lys209 4.8	Lys34 2.4 Gln36 2.1 Lys37 4.4 Cys39 -2.7 Glu67 -3.4 Gly83 2.4 Asp108 -2.7 Val157 -2.2 Asn173 2.8 His174 -3.0 Ala175 -2.7 Lys203 2.3 Trp206 -4.6 Lys209 2.3	Asp35 -3.5 Gln36 6.4 Asn38 2.7 Cys39 -4.2 Glu67 -2.7 Asp72 -2.8 Asp81 -7.7 Asp108 -4.1 Val157 -6.3 Asn173 4.7 His174 -2.4	Gln36 4.3 Gly40 5.3 Cys42 -4.1 Glu67 -2.4 Cys80 2.6 Gly83 5.1 Asn153 -2.9 Asp154 -3.1 Val157 -3.1 Pro172 3.6 Asn173 -3.4 His174 -4.9 Ala175 -2.1
KP-2	Asp36 -3.2 Gln37 -4.7 Cys40 -2.2 Cys43 -4.0 Glu68 -2.7 Asp82 -3.0 Asp109 -4.0 Asp155 -4.2 Asp156 -3.3 Glu161 -2.2 His175 -8.2 Ala176 -2.0 Arg204 3.0 Trp207 -2.7 Lys210 4.	Asp36 -3.2 Cys43 -3.0 Asp109 -2.3 Asp155 -3.0 Asn174 3.3 His175 -2.5	Lys38 3.1 Asp109 -2.2 Trp207 -5.0 Lys210 5.1	Gln37 -4.2 Cys40 -4.0 Glu68 -2.5 Asp82 2.0 Asp109 -2.9 Asn174 5.1 His175 -5.6 Arg204 2.4 Trp207 -3.2 Lys210 2.2 Glu235 -2.5	Lys35 2.3 Gln37 -3.8 Cys40 -2.1 Cys43 -4.0 Glu68 -3.3 Asp82 3.0 Gly84 2.6 Arg88 2.7 Asn174 2.1 His175 -5.1 Ala176 -3.9 Arg204 2.1 Asp231 -2.7 Glu234 -2.6 Glu235 -5.4	Asp36 -2.3 Cys40 -2.5 Trp207 -10.6 Lys210 9.4 Trp211 -2.6	Asp36 2.5 Gln37 -6.4 Cys40 -3.8 Ala42 -2.2 Cys43 -6.2 Glu68 -2.8 Asp82 -4.2 Arg88 4.0 Asp92 -2.0 His175 -4.4 Ala176 -3.2 Trp207 -3.3 Lys210 2.1 Lys228 2.1 Asp231 -3.5 Glu234 -2.8	Lys35 2.5 Gly41 4.0 Glu53 -2.3 Glu68 -3.8 Asp73 -2.0 Lys77 2.1 Arg88 4.7 Glu91 -2.1 Asp92 -2.6 His175 -3.9 Ala176 -2.4 Arg204 2.7 Lys228 2.0 Asp231 -2.6 Glu234 -2.6 Glu235 2.7	Lys35 2.1 Asp36 -3.2 Gln37 2.7 Gly41 2.5 Cys43 -2.3 Glu68 -2.8 Gly84 4.5 Asp155 -2.7 Pro173 -2.1 His175 -2.3 Ala176 -2.3 Arg204 2.3 Lys210 3.0

KP-3	Lys33 2.2	Asp34 -2.4	Asp34 -2.9	Asp34 -2.3	Lys33 2.3	Lys33 2.8	Asp34 -3.1	Asp34 -2.4	Asp34 -3.1
	Asp34 -3.2	Gln35 3.2	Gln35 4.4	Asp37 -2.9	Asp34 -2.6	Asp34 -2.6	Asp37 -4.0	Gly39 3.3	Asp37 -4.0
	Gln35 3.2	Glu66 -2.1	Cys41 -2.4	Glu66 -2.4	Glu66 -3.2	Cys38 -3.7	Glu66 -2.6	Trp42 2.2	Glu66 -2.6
	Glu66 -3.0	Gly82 5.3	Glu66 -2.3	Phe83 -4.6	Gly82 2.6	Glu51 -2.3	Asp71 -2.1	Glu66 -2.6	Asp71 -2.1
	Gly82 3.5	Phe83 -3.5	Gly82 4.0	Arg86 3.4	Phe83 -2.6	Glu66 -4.0	Asp80 -3.1	Asp80 -2.7	Asp80 -3.1
	Asn148 2.7	Asn148 2.3	Phe83 -2.6	Asn148 2.6	Arg86 2.1	Gly82 2.8	Gly82 4.7	Gly82 5.4	Gly82 4.7
	Asn172 -3.9	Thr171 4.1	His173 -3.4	Asn172 2.2	Asn172 4.0	Asn148 2.3	Phe83 -3.0	Glu108 -2.5	Phe83 -3.0
	His173 -2.9	His173 -4.3	Ala174 -2.6	His173 -2.5	Ala174 -2.3	Asn172 2.8	Glu108 -4.8	Thr171 3.9	Glu108 -4.8
	Ala174 -2.3	Trp205 2.2	Trp205 -2.3	Ala174 -2.4	Lys202 2.2	Ala174 -3.0	Asn148 7.1	Asn172 -4.0	Asn148 7.1
	Lys202 2.2				Glu233 -3.8	Lys202 2.8	Thr171 5.7	His173 -2.8	Thr171 5.7
					Glu233 -3.3	Asn172 -2.3	Ala174 -2.1	Asn172 -2.3	
						Ala174 -2.3	Glu233 -3.0	Ala174 -2.3	
BP-2	Asp36 -2.1	Asp36 -4.0	Ala41 -3.8	Asp36 -3.0	Asp36 -5.1	Glu82 -2.2	Lys35 2.8	Lys35 2.2	Asp36 -4.7
	Gln38 -2.4	Lys39 6.8	Glu82 -2.4	Lys39 3.1	Gln37 2.2	Gly83 -2.1	Asp36 -3.7	Asp36 -4.2	Gln37 2.9
	Cys40 -8.6	Cys40 -6.4	Gly84 3.3	Cys40 -3.7	Lys39 2.6	Gly84 -2.6	Gln37 2.9	Gln37 3.8	Glu68 -2.6
	Ala41 -4.7	Ala41 -4.2	Ile85 -4.3	Ala41 -4.6	Glu68 -2.2	Ile85 -10.8	Lys39 3.2	Lys39 2.2	Phe79 -2.1
	Glu68 -2.8	Asp154 -3.1	His175 -2.2	Glu68 -3.0	Val153 -2.0	Ala173 2.5	Ala41 -2.2	Cys43 -3.4	Ile85 -7.1
	Asp155 -2.2	Asp155 -3.9		Glu82 -2.9	Asp154 -4.5		Cys43 -4.0	Glu68 -3.6	Val153 -2.4
	Arg204 2.7	Asp156 -2.7		Val153 -2.3	Asp155 -3.9		Glu68 -3.8	Glu82 -2.6	Asp154 -5.0
	Trp207 -8.0	Glu158 -6.0		Asp154 -3.0	Asp156 -2.7		Asp73 -2.2	Asp154 -3.6	Asp155 -3.0
	Asp210 -2.4	Arg204 2.4		Asp155 -3.3	Glu158 -2.7		Glu82 -3.2	Asp155 -4.9	Asp156 -2.2
		Trp207 -6.5		Asp156 -2.8	Arg204 3.3		Asp154 -4.4	Asp156 -3.5	Asp171 -2.3
		Asp210 -4.3		Glu158 -6.2	Trp207 -9.9		Asp155 -5.3	Asp158 -8.6	Ala173 2.1
				Glu168 -2.4	Glu209 -2.2		Asp156 -3.3	Asn174 3.3	Asn174 2.1
				Asn174 3.1	Asp210 -5.2		Glu158 -7.2	His175 -6.3	Trp207 -2.1
				His175 -6.4	Glu213 -2.1		Asn174 3.9	Ala176 -3.0	
				Arg204 3.8			His175 -5.7	Arg204 4.2	
				Trp207 -6.0			Ala176 -3.3	Trp207 -8.9	
			Asp210 -3.8			Arg204 4.4	Glu209 -2.6		
						Trp207 -9.5	Asp210 -3.6		
						Glu209 -2.3	Glu213 -2.4		
						Asp210 -5.7	Arg214 2.2		
						Glu213 -2.2			
						Arg214 2.1			
CP-2	Asp36 -2.1	Gln37 -2.9	Gln37 -2.7	Gln37 -2.7	Gln37 -3.4	Ala41 -2.5	Asp36 -2.6	Lys38 4.0	Asp36 -2.3
	Glu155 -3.2	Arg39 9.6	Lys38 2.3	Lys38 2.3	Lys38 2.9	Ser154 -3.2	Lys38 2.5	Cys40 -3.0	Cys43 -3.4
	Asp156 -2.1	Cys40 -6.4	Arg39 8.6	Arg39 8.6	Arg39 7.9	Glu155 -4.7	Arg39 2.1	Ala41 -4.3	Glu68 -2.2
	Gln158 2.1	Ala41 -5.5	Ala41 -5.0	Ala41 -5.0	Cys40 -2.5	Asp156 -2.0	Cys40 -2.6	Cys43 -3.2	Cys81 2.3
	Phe172 -2.0	Glu155 -2.9	Cys43 -3.9	Cys43 -3.9	Ala41 -5.3	Gln158 2.1	Ala41 -3.9	Glu68 -2.4	Glu82 4.4

	Asn174 2.9 Trp207 -6.5	Asp159 -2.7 Trp207 -6.2	Glu155 -2.2 Gln158 2.4 Asn174 3.2 His175 -8.4 Trp207 -6.1	Glu155 -2.2 Gln158 2.5 Asn174 3.2 His175 -8.4 Trp207 -6.0	Cys43 -3.1 Glu155 -3.2 Gln158 2.6 His175 -10.7 Trp207 -5.7	Glu168 -3.1 His175 -2.3	Glu68 -2.3 Ile85 -3.4 Glu155 -5.0 Phe172 -3.3 Arg204 2.3 Trp207 -2.6	Phe172 -3.3 His175 -3.5	Gly84 5.2 Ser154 -2.0 Glu155 -5.0 Asn174 -4.7 His175 -4.0 Ala176 -2.4 Arg204 2.0
YP-2	Asp36 -5.4 Gln37 7.2 Glu68 -2.8 Gly83 -2.0 Ile85 -5.6 Asp155 -2.4 Asp156 -2.1 Ala176 -2.8 Arg204 3.2	Phe79 -2.9 Ile85 -9.2 Tyr172 -5.2	Ile85 -8.2 Val153 -2.1	Lys35 2.1 Asp36 3.1 Ala41 -3.9 Cys43 -2.3 Glu68 -2.9 Asp155 -3.0 Asp156 -2.4 Glu158 -2.5 Glu168 -2.1 His175 -5.0 Arg204 3.0 Trp207 -7.5	Cys40 -2.0 Ala41 -4.8 Cys43 -4.3 Glu68 -2.5 Asp82 -2.8 Asp155 -2.9 Asp156 -2.2 Glu158 -4.9 Asn174 4.9 His175 -4.9 Arg204 2.0 Trp207 -6.9	Phe79 -2.4 Gly84 2.3 Ile85 -8.0 Asn174 -2.0 His175 -2.1	Lys39 3.2 Ala41 -3.2 Glu68 -2.8 Ile85 -5.5 Asp155 -2.3 Glu158 -4.5 Asn174 3.6 His175 -2.8 Ala176 -2.8 Arg204 2.7	Asp36 -5.0 Gln37 4.0 Glu68 -2.6 Gly84 4.1 Ile85 -4.8 Asp155 -2.7 Glu158 2.5 Asn174 -2.3 His175 -2.9 Ala176 -2.5 Arg204 2.5 Trp207 -2.4	Glu68 -2.0 Asp82 2.5 Gly84 3.6 Ile85 -2.3 Val153 -3.3 Ala154 -3.0 Asp155 -7.0 Asp156 -2.4 Glu158 5.8 Tyr172 -2.1 Ala173 2.2 Asn174 -3.1 His175 -4.3 Ala176 -2.1